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Sommario: 
 
Il tumore pancreatico rappresenta una delle maggiori sfide per il XXI secolo a 
causa della sua prognosi infausta.  Tra le vie di segnalazione che regolano 
l’aggressività del tumore pancreatico, la via delle MAPK gioca un ruolo chiave in 
questo processo. In particolare, è stato dimostrato che le MAP3Ks agiscono sia 
sulla chemioresistenza che sulle capacità metastatiche di diversi tipi di tumore 
regolando le vie di segnalazione di NFkB e di YAP/TAZ.  
Abbiamo focalizzato la nostra attenzione su due specifici membri delle MAP3Ks, 
TAK1  (TGF-β-activated kinase 1) e MEKK3 (Mitogen-Activated protein Kinase 
Kinase Kinase 3), con lo scopo di capire se e come queste due chinasi fossero 
coinvolte nella regolazione dell’attività dei cofattori trascrizionali YAP/TAZ.  
In primo luogo, abbiamo osservato che il silenziamento di TAK1 causa una 
deregolazione della via di segnalazione di HIPPO, andando a modificare i livelli 
proteici di YAP/TAZ. Nel nostro studio abbiamo dimostrato per la prima volta 
che TAK1 è in grado di regolare la stabilità di YAP/TAZ, indipendentemente 
dalla sua attività chinasica. Abbiamo osservato, infatti, che il silenziamento di 
TAK1 modificava i livelli di espressione di due importanti ubiquitin ligasi come 
TRAF6, che media l’ubiquitinazione K63, e ITCH/AIP4, che promuove 
l’ubiquitinazione K48. 
A seguito di uno studio in cui viene dimostrato che l’inibizione farmacologica di 
GSK3 induce una riduzione dei livelli proteici di TAK1, abbiamo trattato le linee 
cellulari di tumore pancreatico con tre diversi inibitori di GSK3 ed abbiamo 
riscontrato un’importante riduzione dei livelli proteici sia di TAK1 che di 
YAP/TAZ.  Inoltre, abbiamo dimostrato che il silenziamento farmacologico di 
TAK1 inibisce alcuni processi regolati da YAP/TAZ, come la proliferazione e la 
migrazione, riducendo così l’aggressività del tumore pancreatico.   
Parallelamente, abbiamo studiato il ruolo di MEKK3 nel guidare l’aggressività del 
tumore pancreatico. A questo scopo, abbiamo deleto MEKK3 in diverse linee 
cellulari utilizzando la nuova tecnologia di CRISPR-Cas9. Successivamente, 
abbiamo valutato l’effetto della delezione sulle diverse caratteristiche del tumore 
pancreatico. In particolare, abbiamo osservato un’importante riduzione 
dell’invasività, della proliferazione e della capacità di formare colonie in cellule 
delete per MEKK3. Parallelamente, abbiamo valutato l’effetto della delezione di 
MEKK3 sull’attività delle vie di segnalazione di NFkB e YAP/TAZ. Sebbene non 
abbiamo riscontrato nessun’alterazione nella via di segnalazione di NFkB, 
abbiamo dimostrato che la delezione di MEKK3 riduceva l’attività trascrizionale 
di YAP/TAZ, senza alterare i loro livelli proteici. 
Il ruolo emergente di YAP/TAZ nel guidare lo sviluppo e l’aggressività del 
tumore pancreatico sottolinea l’esigenza di identificare nuovi farmaci in grado di 
inibire la loro attività. Attualmente non esistono farmaci specifici per inibire 
YAP/TAZ e l’identificazione di farmaci in grado di bloccare l’azione di cofattori 
trascrizionali è molto complicata. I nostri dati dimostrano che, nel tumore 
pancreatico, l’attività di YAP/TAZ può essere ridotta attraverso l’inibizione 
farmacologica sia di GSK3/TAK1 che di MEKK3. 
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Abstract: 
Pancreatic cancer (PC) remains one of the most lethal and poorly understood 
human malignancies and will continue to be a major unsolved health problem in 
the 21st century.  The MAP3K pathway is one of most important pathways that 
regulate the aggressiveness of PC. In particular, MAP3Ks act by regulating NFkB 
and YAP/TAZ signaling, two of the most well characterized pathways sustaining 
the chemoresistance and EMT features of this cancer.  
We focused our attention on two members of the MAP3K pathway, the TGF-β-
activated kinase 1 (TAK1) and the Mitogen-Activated protein kinase kinase kinase 
3 (MEKK3) with the aim to understand whether and how they could impact on 
YAP/TAZ.  
We showed that TAK1 silencing affects the HIPPO pathway by modulating 
YAP/TAZ protein levels. We reported for the first time that TAK1 can regulate the 
stability of YAP/TAZ, independently on its kinase activity, by modulating the 
expression of E3-ubiquitin ligases, such as TRAF6 and ITCH/AIP4. Moreover, 
based on a recent report showing that the pharmacological inhibition of GSK3 
caused a reduction of TAK1 levels, we treated our cells with GSK3 inhibitors and 
we observed a reduction of both TAK1 and YAP/TAZ proteins, as well as 
YAP/TAZ regulated genes. Pharmacological silencing of TAK1 impaired 
YAP/TAZ-regulated features, such as proliferation and migration. 
As for MEKK3, we knocked out its expression in different cellular models by 
CRISPR-Cas9 technology. Then, we assessed the impact of MEKK3 knock-out 
(MEKK3 KO) on the aggressiveness of PC. We observed a decrease of 
proliferation and colony formation ability in MEKK3 KO cells. Simultaneously, we 
observed that MEKK3 KO affects the YAP/TAZ target genes expression, without 
altering YAP/TAZ protein levels or the NFkB pathway. 
The emerging role of YAP/TAZ in orchestrating the development and the 
sustainment of PC opens the need for the discovery of drugs to inhibit their 
activities but, so far, no specific inhibitors of YAP/TAZ have been identified. 
Our data open the path for targeting the YAP/TAZ pathway through 
pharmacological inhibition of GSK3/TAK1 and MEKK3.  
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1. Background 
 
 
 
 
1.1.Pancreatic Cancer 
 
1.1.1 Epidemiology 
 
Pancreatic cancer (PC) remains one of the most lethal and poorly understood 
human malignancies, and will continue to be a major unsolved health problem in 
the 21st century 
1
. It has been estimated that in 2016 there were 53,070 new cases 
of pancreatic adenocarcinoma with approximately 41,780 deaths in the United 
States. Because of our inability to detect PC at an early stage and the lack of 
effective systemic therapies, only 1-4% of patients with adenocarcinoma of the 
pancreas will be alive 5 years after diagnosis. Thus, incidence rates are virtually 
identical to mortality rates. In the United States in 2016, PC will be the fourth 
leading cause of adult death from cancer and will be responsible for close to 7% 
of all cancer-related deaths 
2
. 
 
1.1.2 Genetics and risk factors 
 
Less then 10% of PC cases can be accounted for by hereditary genetic factors. 
Germline mutations in Serine Protease 1 (PRSS1), Serine/Threonine Kinase 11 
(STK11), Cyclin Dependent Kinase Inhibitor 2A (CDKN2a), Breast Cancer Type 
2 Susceptibility Protein (BRCA2), or mismatch repair genes may account for less 
than 20% of inherited PC 
3
. Several genetic syndromes, such as hereditary 
pancreatitis, hereditary nonpolyposis colorectal cancer and familial breast cancer, 
have been associated with an increased risk of PC 
4,5
. 
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Pre-existing chronic pancreatitis has been associated with a 10-20 fold increased 
risk of PC 
6
. Specifically, a multicentric cohort study of 2000 patients with 
chronic pancreatitis reported a 16-fold increased risk of PC 
7
.  
Smoking has been consistently and convincingly linked to a marked increased risk 
of PC. In fact, studies have shown a correlation between the number of smoked 
cigarettes and the incidence of PC. In general, cigarette smoking has been 
estimated to account roughly 25-29% of the overall incidence of PC in the United 
States 
8–10
. In particular, cigarettes smokers show up to 2,5 fold increased risk of 
developing PC as compared to nonsmokers 
11
. 
Similarly, obesity is another important risk factor correlated with PC development 
and poor prognosis. In particular, it has been shown in three recent large pooled 
analyses that a BMI higher than 30 Kg/m
2
 increases the risk to develop PC up to 
20-50% as compared to normal BMI participants
12
. 
 
1.1.3 Histology 
 
The most common malignancy of the pancreas is the infiltrating ductal 
adenocarcinoma. Infiltrating ductal adenocarcinoma, commonly known as 
"pancreatic cancer", is defined as an invasive malignant epithelial neoplasm with 
ductal differentiation 
13
. The majority (60-70%) of PC arise in the head of the 
gland, most are poorly defined and they compromise the normal lobular 
architecture of the pancreas 
14
. 
Pancreatic ductal adenocarcinomas (PDAC) are characterized by two remarkable 
features at the microscopic level. First, they elicit an intense desmoplastic 
reaction. As a result, most of the cells that comprise the mass produced by a PC 
are non-neoplastic fibroblasts, lymphocytes and macrophages. Second, despite the 
highly lethal nature of PC, most of these neoplasms are remarkably well-
differentiated. Features supportive of a diagnosis of PC include perineural 
invasion, vascular invasion, a haphazard arrangement of the glands, nuclear 
pleomorphism, the presence of a gland immediately adjacent to a muscular artery, 
and luminal necrosis 
13
. Immunohistochemical labeling can be used to 
characterize the direction of differentiation of the neoplastic cells. Most pancreatic 
cancers express several cytokeratins, such as CK7, 8, 13, 18, 19, 
carcinoembryonic antigen (CEA) and carcinoma antigen 19-9 (CA19-9) 
15,16
.  
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1.1.4 Molecular pathogenesis of pancreatic 
cancer 
 
While our knowledge of the genetic events that underpin multistep carcinogenesis 
in PC has increased dramatically, and despite a steady identification of new 
targets and new drugs for clinical testing, researchers still continue to work with 
an incomplete understanding of how the complex molecular biology contributes to 
the aggressive behavior of this disease.  
In contrast to many epithelial malignancies, PC is characterized by four genes that 
are altered in the majority of patients: the KRAS proto-oncogene is mutated and 
constitutively activated in >90% of cases, while the tumor suppressors cyclin-
dependent kinase Inhibitor 2A (CDKN2A), p53, and DPC4/SMAD4 are mutated 
in >95%, 50-75%, and 55% of cases respectively 
17
. In particular, has been 
demonstrated that constitutive activation of KRAS alone in the pancreatic 
epithelium drives the development of premalignant ductal neoplasias known as 
pancreatic interepithelial neoplasias (PanINs) in mice 
18
. The consecutive loss or 
mutation of tumor suppressors, such as CDKN2A, p16 and p53 leads to the 
development of highly aggressive PDAC
19,20
. In addition, SMAD4 inactivation, 
that occurs in half of PC patients, is correlated to a highly aggressive metastatic 
phenotype of PDAC 
21
. These alterations confer high genomic instability and 
aggressive features to PC. 
 
1.1.5 Treatment 
 
Despite efforts over the past century, conventional therapeutic approaches, such as 
surgery, radiation, chemotherapy, or combinations of these modalities, have not 
had much impact on the course of this aggressive disease 
22
. The outlook of 
individuals with PC is dismal as described by the following statistics. Over 80% 
of patients with PC have advanced disease at time of diagnosis and are not 
candidates for a potentially curative resection. In this group of patients, 
approximately 20% will have locally advanced disease with a median survival of 
8-12 months, and 50% will have metastatic disease with median survival of 3-6 
months. Of the remaining patients who undergo a resection, the chance of long-
term survival is low; 80-90% will go on to have recurrence. One-half of patients 
undergoing a potentially curative resection will be dead of disease in 18 months, 
and less then 20% will be alive at 5 years 
23
. Certain pathologic features such as a 
tumor size less than 2 cm, absence of spread to regional lymphnodes, and a 
surgical margin free of carcinoma are good prognostic indicators 
24
. Under ideal 
circumstances, in which all of these factors are favorable, 5-year survival is 
achieved in only 43% 
23
. The major factors contributing to the lethality of this 
disease are the inability to detect early cancers and ineffective systemic therapy. 
The only chance for long-term survival in patients with PC is with surgical 
resection. However, since the majority of patients have occult systemic disease at 
the time of resection, cure relies on systemic therapy. The first line treatment of 
10 
 
advanced PC consists in chemotherapies characterized by combination of 
gemcitabine with FOLFIRINOX, a cocktail of folinic acid, fluorouracil, irinotecan 
and oxaliplatin, or with nab-paclitaxel.  This is the main front-line treatment 
option for patients with good performance status at the time of diagnosis. In spite 
of the aggressiveness of PC, nearly half of patients who have progressed on front-
line therapy are able to receive second-line therapy. A fluorouracil-based regimen 
is used for patients who progress through gemcitabine, while patients who 
received FOLFIRINOX in the first-line, are treated with gemcitabine-based 
therapy in the second line 
25
. 
 
1.2 Mitogen-activated kinase signaling 
 
Mitogen-activated protein kinase (MAPK) signaling transduction pathways are 
ubiquitous and highly conserved mechanism of eukaryotic cell regulation 
26
.  
Different MAPK pathways are able to integrate and coordinate the responses to 
different extracellular stimuli, including hormones, growth factors, cytokines, 
transforming growth factor (TGF)-β related agents and stresses, such as toxins, 
drugs exposure, change in cellular adherence, oxygen radicals and ultraviolet light 
27
.   
The MAPKs phosphorylation cascade is orchestrated by three levels of activating 
phosphorylations mediated by Mitogen-Activated Protein Kinase Kinase Kinase 
(MKKKs or MAP3Ks) that phosphorylate Mitogen-Activated Protein Kinase 
Kinase (MKKs or MAP2Ks) phosphorylating in turn MAPKs 
27
. In particular, 
MAPKs are activated via simultaneous Thr and Tyr phosphorylation within a 
distinct and conserved Thr-X-Tyr motif in the kinase activation loop. Conversely, 
MAP2Ks are activated by a pattern of different MAP3Ks through Ser-Thr 
phosphorylation in the conserved kinase domain 
28
.  MAP3Ks constitute the 
largest group of MAPKs, composed of at least twenty proteins, such as TAK1, 
MEKK3 and TPL2, as compared to seven MAP2Ks and eleven MAPKs, such as 
ERK1/2, c-Jun N terminal Kinases (JNKs) and p38 (Fig. 1) 
29
. 
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Fig 1.  Mammalian MAPK Signaling Cascade.  A broad range of extracellular stimuli including 
mitogens, cytokines, growth factors, and environmental stressors stimulate the activation of one or 
more MAPKK kinases (MAPKKKs) via receptor-dependent and -independent mechanisms. 
MAPKKKs then phosphorylate and activate a downstream MAPK kinase (MAPKK), which in 
turn phosphorylates and activates MAPKs. Activation of MAPKs leads to the phosphorylation and 
activation of specific MAPK-activated protein kinases (MAPKAPKs), such as members of the 
RSK, MSK, or MNK family, and MK2/3/5. These MAPKAPKs function to amplify the signal and 
mediate the broad range of biological processes regulated by the different MAPKs. Conventional 
MAPKs include the extracellular signal-regulated kinase 1 and 2 (Erk1/2 or p44/42), the c-Jun N-
terminal kinases 1-3 (JNK1-3)/ stress activated protein kinases (SAPK1A, 1B, 1C), the p38 
isoforms (p38α, β, γ, and δ), and Erk5. The lesser-studied, atypical MAPKs include Nemo-like 
kinase (NLK), Erk3/4, and Erk7/8 
30. 
 
The protein kinases constituting MAPK signaling modules form a series of 
sequential binary interactions to create a protein kinase cascade. These protein 
kinases are organized into signaling complexes that determine the specificity of 
the activated pathways 
31
. All MAPKs substrates are characterized by the presence 
of specific docking sites. Although the docking sites are not necessarily near the 
MAPK phosphor-acceptor sites, they are recognized by a complementary docking 
motif on the MAPKs and mediate a strong and selective interaction between 
specific MAPKs and their substrates. This specificity is increased by the binding 
of scaffold proteins, such as MEK-partner 1 (MP1) and β-arrestin 1 and 2 32. 
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MAPK pathways are essential to regulate several physiological processes and 
carry out their functions by phosphorylating target proiteins and activating 
transcription factors, such as ETS transcription factor (Elk1), c-Jun, and activating 
transcription factor 2 (ATF2). Different studies have demonstrated the 
involvement of these pathways in orchestrating differentiation, proliferation and 
apoptosis. JNKs play a crucial role in the specification of CD4+ T-cells, 
regulating the balance between Th1 and Th2 phenotype. The lack of JNK1 and 
JNK2 impairs the production of IL-2 thus promoting the differentiation of CD4+ 
T-cells into Th2 phenotype. In addition, they promote cellular apoptosis following 
ultraviolet-C (UV-C) exposure and control cytochrome c release and 
mitochondrial apoptosis by regulating the activity of the anti-apoptotic protein 
Bcl2 
33
. On the contrary, p38 does not impact on the differentiation of CD4+ T-
cells into Th1 or Th2 but it regulates Th1 responses and IFN-γ production 34. 
Moreover, it has been demonstrated that p38α negatively regulates cell 
proliferation in multiple cell types and during liver cancer development. Indeed, 
the ablation of p38α in hepatocellular carcinoma cells is correlated with an up-
regulation of the JNK-c-Jun pathway that promotes hepatocytes proliferation 
35
.   
 
1.3. Transforming-growth factor-β 
(TGF-β) activated kinase 1 (TAK1) 
 
The Transforming Growth Factor-β (TGF- β) activated kinase 1 (TAK1) is a 
serine/threonine kinase belonging to the MAP3K family. It has been demonstrated 
that TAK1 plays a critical role in orchestrating inflammatory response and cell 
survival control through the integration of different signaling pathways - including 
TGF-β, interleukin-1 (IL-1), Tumor Necrosis Factors α (TNFα) and Toll-Like 
Receptors (TLR). The main, and well characterized, effectors of TAK1 are two 
transcription factors - nuclear factor κ-B (NF-κB) and activated protein-1 (AP-1), 
and they are activated by specific extracellular stimuli 
36
.  In particular, TAK1 
induces the activation of NF-κB by promoting the interaction between the NF-κB 
inhibitor kinase β (IKK β) complex and TNF Receptor Associated Factor 2 
(TRAF2) or 6 (TRAF6) in TNFα and IL-1/TLR signaling pathways, respectively 
37,38
. IKK β phosphorylates the IκB proteins leading to ubiquitination and, 
consequential degradation by the ubiquitinin-proteosome pathway. Upon 
degradation of IκB, NFκB is able to translocate into the nucleus and drive the 
expression of NFκB target genes 39. 
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1.3.1 Molecular mechanisms of TAK1 
regulation 
 
It has been demonstrated that TAK1 kinase activity is strictly regulated by 
multiple post translational modifications (PTMs), such as 
phosphorylation/dephosphorylation and ubiquitination, and these PTMs are 
orchestrated by TAK1 itself and by several TAK1 associated proteins 
36
.  TAK1 is 
constitutively bound to TAK1 Binding Protein 1 (TAB1), while it binds TAB2 or 
TAB3 only after IL-1 and TNFα stimulations 40. All these binding proteins are 
required to regulate TAK1 activity.  In particular, TAB1 contains a C-terminal 
domain and N-terminal pseudophospatase domain which are necessary to bind and 
activate TAK1, respectively 
41
.   On the other hand, TAB2 or TAB3 act by 
scaffold proteins and promote the interaction of TAK1/TAB1 complex to TRAF6 
protein 
40
. 
TRAF6 is an important ubiquitin ligase that promotes the K63-linked poly-
ubiquitination of different proteins. Unlike K48-linked poly-ubiquitination, that is 
correlated with proteasomal degradation, K63-linked poly-ubiquitination has been 
demonstrated to regulate several signaling functions, such as protein kinase 
activation, DNA repair and vesicle trafficking 
42
. Upon IL-1 stimulation, TRAF6 
mediates a K63-linked poly-ubiquitination of TAK1 kinase complex which 
phosphorylates and activates IKK β 43. In addition to TRAF6, the E3 ubiquitin 
ligase X-linked Inhibitor of Apoptosis (XIAP) has been shown to activate NF-κB 
pathway through the TAK1 ubiquitination 
44
.  
TAK1 K63 poly-ubiquitination is tightly regulated by different deubiquitinatin 
(DUB) enzymes, such as Cylindromatosis (CYLD) and A20, which can negatively 
regulate TAK1, hence inhibiting NF-κB signaling 41.  The tumor suppressor 
protein CYLD contains an ubiquitin-carboxy-terminal-hydrolase (UCH) domain
45
 
through which it hydrolyzes the K63-linked polyubiquitin chains on TRAF6 and 
TRAF2, thereby inhibiting the activity of the TAK1 kinase complex 
46
. Moreover, 
TAK1 stability is regulated by several E3 ubiquitin ligases mediating K48-linked 
poly-ubiquitination, such as ITCH/AIP4. The combined activity of ITCH and 
CYLD shifts TAK1 ubiquitination from K63-poly-ubiquitinationlinked to K48-
linkedpoly-ubiquitination, thereby inducing TAK1 degradation and impairing the 
NF-κB-dependent inflammatory response 47. 
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1.3.2 Signaling pathways triggering TAK1 
activation 
 
TAK1 represents the cellular hub to which IL1, TGFβ and TLR signaling 
pathways converge (Fig.2). 
 
Fig 2. Transforming growth factor b-activated kinase 1 (TAK1) activation and downstream 
signaling pathways. TAK1 activation is triggered by several extracellular stimuli including IL-1, 
LPS and TGFβ. Stimulation of IL-1R and TLR4 promotes the activation of myeloid differentiation 
primary response gene 88 (MyD88) that, in turn, recruits IRAK4, IRAK1 and TRAF6. The 
MyD88/IRAK4/IRAK1 complex promotes the activation of TRAF6, which catalyzes K63-linked 
poly-ubiquitination of TAK1. Moreover for a full activation, TAK1 need to bind TAB1 and 
TAB2/3 proteins. This proteins promote the TAK1 activation by ubiquitination and auto-
phosphorylation. Similarly, stimulation of TβRI and TβRII promotes by non-canonical pathway 
the activation of TRAF6 which, in turn, mediates the poly-ubiquitination and the activation of 
TAK1. Activated TAK1 drives the phopshorylation and the activation of both several MAPKs, 
including p38, JNK and ERK1/2, and NF-κB pathway 48,49. 
 
 IL-1 mediates inflammation and immunity responses through the activation of the 
NF-κB transcription factor 50. The binding of IL-1 to its receptor, IL-1 receptor-1 
(IL1R-1), leads to the activation of TAK1. Stimulation with IL-1 promotes the 
phosphorylation of TAK1 in Thr-178 and Thr-184 
51,52
, both residing in its kinase 
activation loop, as well as the formation of a ternary TAB2-TAK1-TRAF6 
15 
 
complex resulting in TRAF6 mediated K63-linked poly-ubiquitination  of 
TAK1
53,54
.   
The TGFβ growth factor is able to regulate several cellular functions by triggering 
a multitude of intracellular signaling pathways. TGF-β principally exerts its 
effects through the canonical Smad pathway; however, attention is also being 
focused on the non-canonical pathway, triggering MAPKs and NF-κB activation 
through the induction of TAK1 ubiquitination by TRAF6  
55. In particular, TGFβ 
stimulation induces the dimerization of TGFβ receptor 1 and 2 (TβRI and TβRII) 
and the recruitment of TRAF6 to the receptor complex, which undergoes auto-
ubiquitination and causes K63-linked poly-ubiquitination of TAK1 
56
. The 
outcome is p38 phosphorylation and the sustainment of several pro-survival 
pathways, such as NF-κB 57.  
Another level of TAK1 regulation is exerted by Toll Like Receptors (TLRs). 
TLRs constitute a superfamily of pattern recognition receptors, well known for 
their role in host defense from infection 
58
. Several studies demonstrated that 
TLRs are able to orchestrate key processes involved in tumorigenesis, such as 
inflammation, proliferation, migration and angiogenesis 
59,60,61
.  In particular, it 
has been demonstrated that, in response to lipopolysacchatide (LPS), TLR4, 
triggers the IL-1 receptor-associated kinase 1 (IRAK-1) dependent activation of 
TAK1 
62
. 
 
 
1.3.3 Role of TAK1 in normal tissues 
 
The important role of TAK1 in orchestrating several cellular processes has been 
demonstrated through complete or conditional knock-out (KO) of TAK1, TAB1 
or TAB2 in mice. Complete KO of any member of the TAK1 complex results in 
embryonic lethality, due to impaired development of neural tube 
63
, cardiovascular 
apparatus 
64
 and liver 
65
. Conditional KO produces different outcomes. TAK1-/- 
Mouse Embryonic Fibroblasts (MEF) show reduced NF-κB and JNK signaling 
pathways 
63
. Conditional KO of TAK1 in B-lymphocytes shows defect in both 
maturation and activation of B cells, due to the impairment of JNK activation 
66,67
.  
Conditional KO in Natural Killer (NK) cells has shown a reduction of cytokines 
and chemokines secretion, caused by a decrease of NF-κB and JNK activity 68. 
Conversely, TAK1 KO in myeloid cells induces splenomegaly and 
lymphomegaly, associated with neutrophilia and enhancement of both JNK and 
NF-κB activity 69. NF-κB Conditional KO of TAK1 in Hematopoietic 
Stem/Progenitor Cells (HSPC) causes massive apoptosis in spleen, thymus, liver 
16 
 
and bone marrow, together with complete abrogation of both NF-κB and JNK 
signaling in bone marrow 
70
. TAK1 KO in the liver parenchymal cells determines 
hepatocyte dysplasia and liver carcinogenesis 
71
, while epidermal-specific KO 
causes severe inflammatory skin condition and massive keratinocyte apoptosis, 
with impaired NF-κB and JNK signaling 72. 
 
1.3.4 Role of TAK1 in cancer 
 
Epithelial to Mesenchymal Transition (EMT) is the mean process by which cancer 
cells acquire the ability to invade and metastasize to other tissues. EMT is 
triggered by the interplay of soluble factors and cytokines, such as TGF-β and 
components of the extracellular matrix (ECM). The key event in EMT is probably 
the disruption of cadherin junctions, mostly due to the activity of several 
transcription factors repressing the expression of E-cadherin, such as the members 
of the ZEB, Snail and basic helix-loop-helix (bHLH) families. The signaling 
pathways triggering their regulation are constituted by SMADs, MAPK, 
Phosphatidylinositol 3-Kinase (PI3K), Glycogen Synthase Kinase 3 β (GSK3β) 
and NF-κB 73,74. It has been reported that the TAK1/ NF-κB pathway induces 
downregulation of E-cadherin expression, thereby triggering EMT 75. In addition, 
inhibition of TAK1 reverts IL-1β and TGF-β1 induced EMT by reducing the 
transcriptional activity of Smad1-5-8 in mesothelial cells 76, and by inhibition of 
Smad2/3 phosphorylation in retinal pigmental epithelial cells 
77
. TAK1 promotes 
lymphatic invasion in breast cancer through increase in the expression of 
chemokine C-C motif receptor 7 (CCR7), whereas inhibition of its kinase activity 
by treatment with 5Z-7-Oxozeaenol (5Z-O) suppresses both lymphatic invasion 
and lung metastasis 
78,79
. Similar results are observed in ovarian cancer, where 
TAK1 enhances tumor growth and metastatic capacity 
80
, and in colon cancer, 
where TAK1 has been shown to induce cancer cell migration and lung metastasis 
upon TNF-α stimulation by activating both JNK and p38 pathways 81.  
It has been shown that TAK1 is one of the major regulators of chemioresistance in 
several types of tumors. Treatment of PC cells with the orally active TAK1 
inhibitor, LYTAK1, reduced chemoresistance to oxaliplatin, gemcitabine and 
SN38. Moreover, it reduced tumor volume and prolonged survival in mice 
harboring PC xenografts and treated with the above mentioned drugs 
57
. This 
effect is due to a NF-κB and AP1 dependent reduction of anti-apoptotic proteins, 
such as cellular inhibitor of apoptosis 2 (cIAP-2), which regulates programmed 
cell death by direct caspase inhibition and by promoting the degradation of pro-
apoptotic proteins belonging to TNFα signaling 82 NF-κB57. 
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1.4 Mitogen-activated kinase kinase 
kinase 3 (MAP3K3 or MEKK3) 
 
 
Mitogen-activated kinase kinase kinase 3 (MAP3K3 or MEKK3) is a 
serine/threonine kinase belonging to the MEKK/STE11 subgroup of the MAP3K 
family that is costitutively expressed in several types of tissues
 83
. It has been 
demonstrated an important role for MEKK3 in orchestrating cellular processes, 
such as proliferation, cell cycle progression
84
, differentiation, migration, apoptosis 
85,86
 and inflammatory response 
50
, through the integration of different signaling 
pathways. MEKK3 is essential for both TNFα-induced IKK-NF-κB and JNK-p38 
activation and IL1R-TLR4 induced IL6 productionNF-κB. The activation of the 
NF-kB and AP-1 transcription factors is exerted by different MEKK3-regulated 
kinases such as IKK, JNK1/2, p38, and ERK5 , upon specific extracellular stimuli 
83,87,88
. 
 
 
1.4.1 Molecular mechanisms of MEKK3 
regulation 
 
The mechanisms regulating MEKK3 activation are still not fully understood. It 
has been demonstrated that several activating phosphorylations can occur within 
the kinase activation loop on Thr-516, Ser-520 and Ser-526, which might be due 
to either  MEKK3 itself or other kinases following specific stimulation 
89,90
. 
Several studies have demonstrated the involvement of accessory proteins, such as 
TRAF6 and 14-3-3, in promoting MEKK3 activation 
50,91
. In particular, by 
interacting with p62, TRAF6 recruits MEKK3 on its zinc-finger domain, thereby 
promoting the oligomerization and the autophosporylation of MEKK3 in Ser-526 
50,92
.  Phosphorylation in Ser-526 of MEKK3 promotes indirectly the recruitment 
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of 14-3-3ε to MEKK3. This interaction prevents dephosphorylation of Ser-526 by 
protein phosphatase 2 A (PP2A) thus sustaining MEKK3 activation 
91
 
93
. Indeed, 
dephosphorylation of MEKK3 in Thr-516, Ser-520 and Ser-526 by PP2A is a 
main mechanism of inhibition of MEKK3-mediated signal transduction pathway 
94
. However, it remains unclear how and which members of the protein 
serine/threonine phosphatase family inhibit MEKK3 activation. 
 
1.4.2 Signaling pathways triggering MEKK3 
activation 
 
MEKK3 is a key signaling molecule downstream several pathways, such as TNFα 
87
, IL1 
50
 and TLR4 
88
, and its activity regulates, through NF-κB and AP1, the 
expression of many inflammatory response gene including pro-inflammatory 
cytokines, anti-apoptotic elements and growth factors 
83,87,95
.  
Following IL-1 binding to its receptor, the formation of a receptor complex, 
constituted by IL1R-1 and IL1R accessory proteins, occurs. Subsequently, MyD88 
is recruited to this complex and mediates the recruitment of IRAK1 and IRAK4 
96,97
. IRAK4 phosphorylates and activates IRAK1 which in turn recruits TRAF6 
98,99
. This multiprotein complex regulates two MEKK3 dependent pathways, the 
Ring finger and the Zinc finger pathways (Fig. 3).  
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Fig. 3 IL-1 induces NF-κB activation by two mechanistically and temporally distinct pathways.  
The RING pathway transduces IL1 signaling by inducing the formation of a 
TRAF6/MEKK3/TAK1/IRAK1 signaling complex. K63-linked poly-ubiquitination of TRAF6 triggers 
the recruitment of TAB2/3 into the signaling complex, while K63-linked poly-ubiquitination of 
TAK1 promotes the binding of MEKK3 and its associated proteins. Within this complex, MEKK3 
enhances TAK1 activity. In addition, following K63-linked poly-ubiquitination of IRAK1 IKK is 
recruited into the signaling complex thus activating the NF-κB pathway. On the other hand, the 
Zinc pathway is independent on TAK1 but MEKK3-dependent. Upon IL-1 stimulation, IRAK1 and 4 
activate TRAF6 which, in turn, promotes the oligomerization and the autophosphorylation of 
MEKK3. Activated MEKK3 triggers the activation of the IKK complex and, thus, of the NF-κB 
pathway. While the RING pathway is triggered within one hour from IL-1 stimulation, the Zinc 
pathway drives NF-κB activation only afterwards 
50
. 
 
In the Ring pathway, the IRAK1/TRAF6 complex translocates from the 
membrane to the cytosol where it binds both MEKK3 and TAK1 
41,88
. In this 
complex, MEKK3 may activate TAK1 by phosphorylation in Thr178, Thr184 and 
Thr187, thus promoting NF-κB activation 100. In the Zinc pathway, instead, 
TRAF6 forms a complex with MEKK3 and promotes its oligomerization and, 
activation 
50
, which induces in turn the activation of the IKK complex by 
p38MAPK and promotes NF-κB signaling 88. 
The proinflammatory cytokine TNFα is a soluble factor that strongly activates the 
NF-κB signaling pathway 101. Upon TNFα treatment, both the IKK complex and 
MEKK3 are recruited to TNF receptor 1 (TNFR1) by TRAF2 and Receptor 
Interacting Protein (RIP) respectively 
87,102
. It has been demonstrated that MEKK3 
is necessary for the TNFα-induced activation of IKK complex and the NF-κB 
pathway. In accordance to this observation, MEKK3-/- Mouse Embryonic 
Fibroblasts (MEFs) show a downregulation of NF-κB-dependent antiapoptotic 
genes which makes them more sensitive to TNFα-induced apoptosis than MEF 
wild type 
87
. 
LPS can activate NF-κB through IL-1R-TLR4 signaling in a MEKK3 dependent 
manner 
103
. In particular, MEKK3 regulates the IL-1R-TLR4-induced IL-6 
production through the activation of both JNK-p38 MAPK and IKK-NF-κB 
pathway. Knock-out of MEKK3 reduced the activation of  MAPK kinase 6 
(MKK6) and 7 (MEKK7), resulting in the loss of LPS-dependent p38 MAPK and 
JNK activation 
104,88
.   
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1.4.3 Role of MEKK3 in normal tissues 
 
The important role of MEKK3 in orchestrating cellular processes has been also 
demonstrated through complete or conditional knock-out (KO) of MEKK3.  
Complete KO of MEKK3 causes embryonic lethality due to impaired 
cardiovascular development, endothelial cells proliferation and muscle cell 
formation 
105,106
. Conditional KO mice harbored different phenotypes. Mice with 
T cell conditional ablation of MEKK3 have a significant reduction in peripheral T 
cells number, but do not present any alteration in the thymic T cells development 
and maturation 
107
. Other studies have demonstrated that MEKK3 conditional KO 
in T cells leads to the accumulation of regulatory T (T reg) and Th17 cells in the 
periphery 
108
. Conditional KO of MEKK3 in endothelial cells induces an increase 
of hemorrhages in multiple organs, especially in the brain 
109
. 
 
 
1.4.4 Role of MEKK3 in cancer 
 
Activation of the ERK pathway through hyperactivation of MAPKs signaling, is a 
hallmark of cancer development 
110
. The epidermal growth factor (EGF) is 
involved in the pathogenesis of several types of tumors and its overexpression has 
been revealed in human carcinomas 
111
. EGF receptor (EGFR) triggers an Erk5-
dependent overexpression of the proto-oncogene c-Jun and consequent increase in 
cell proliferation 
112
.  It has been demonstrated that MEKK3 plays a major role in 
regulating EGF-induced cell proliferation by inducing endogenous Erk5 through 
the activation of MEK5 
84
. 
The role of MEKK3 in orchestrating many cellular processes important for the 
embryonic development is well known 
113
. Only in the last years, the involvement 
of MEKK3 in driving the development and the malignancy of different tumors, 
such as lung, breast and esophageal cancers, has been studied 
114–116
. More in 
details, MEKK3 is able to induce proliferation, migration and invasion of lung 
cancer cells, through the activation of AKT and GSK3β signaling pathways 114. In 
particular, MEKK3 knock-out causes a reduction of cell proliferation and 
invasion, by downregulating genes such as CDC25A and CDK2, which promote 
cell proliferation, as well as DKK1 that promotes the invasiveness of cancer 
114,117
. 
Overexpression of MEKK3 has been shown also in breast cancer and it is 
correlated with metastatization and survival of cancer cells. Silencing of MEKK3 
reverts the malignant behavior of breast cancer cells; in particular MEKK3 
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knockdown in MCF7 cells impacts both on EMT through a downregulation of 
vimentin, and on cancer motility by a reduction of Intercellular Adhesion 
Molecule 1 (ICAM1) expression
118
.  Moreover, the role of MEKK3 in driving the 
chemioresistance of ovarian and breast cancer has been also investigated; 
silencing of MEKK3 sensitizes cancer cell to apoptosis induced by both TNFα 
and chemotherapeutic agents, through the inhibition of the NF-κB pathway 
115,118,119
. The clinical relevance of MEKK3 has been verified by Hasan et al.. 
They demonstrated that MEKK3 overexpression occurs in early stages of 
esophageal squamous cell carcinoma and, in combination with lymph-node 
positivity, it could be used as negative prognostic factor for this tumor 
116
. 
 
 
1.5. The Hippo pathway 
 
 
The Hippo pathway is crucial for the correct development of different organs and 
its dysregulation contributes to tumorigenesis 
120
. Knock-out of the genes 
belonging to the Hippo pathway, such as Mammalian STE20-Like Protein Kinase 
1 and 2 (MST1/2), Large Tumor Suppressor kinase 1 and 2 (LATS1/2) and 
Salvador Homolog 1 (SAV1), leads to increased organs size, due to both 
excessive cell proliferation and defective apoptotic program 
121–123
. The Hippo 
pathway is constituted by the kinases MST1/2 and LATS1/2, the scaffold proteins 
SAV1 and MOB1A/B, and the transcriptional co-factors Yes-associated protein 
(YAP) and Transcriptional Coactivator With PDZ-Binding Motif (TAZ), which 
control the expression of Hippo target genes. Upon activation of the Hippo 
pathway, MST1/2 phosphorylate and activate LATS1 which, in turn, 
phosphorylates YAP and TAZ thereby inducing their cytoplasmic translocation 
and degradation 
124,125
 
126
. When the Hippo pathway is inactive, YAP and TAZ 
translocate into the nucleus and drive the expression of genes such as CTGF, 
AXL, CYR61, FosL1 and DKK1, involved in cell cycle progression, cell 
proliferation, differentiation, angiogenesis, stress response, apoptosis, and 
extracellular matrix formation 
127–132
 
120
. Being unable to bind DNA consensus 
sequences directly, YAP/TAZ form complexes with transcription factors, such as 
TEA domain family members (TEADs), AP1, SMADs and Nucleosome 
Remodeling Deacetylase (NuRD) complex, to exert their functions 
127,133,134
, and 
the binding to either transcription factor confers them characteristics of 
transcriptional co-activators or co-repressors.   
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1.5.1 Signaling pathways involved in 
YAP/TAZ regulation 
 
The Hippo pathway activity is regulated by different stimuli including cell-cell 
and cell-matrix adhesion, matrix stiffness, mechanical stress and cell 
metabolism
120
. Moreover, YAP/TAZ is the hub for several signaling pathway such 
as EGF, TGFβ and canonical or non-canonical Wnt pathways 135,136.  In particular, 
the interplay between Wnt and YAP/TAZ pathway seem to be important in 
orchestrating several cancer processes including cell motility and tumorigenesis 
137,138
.   
WNT is a family of growth factors that elicit diverse Frizzled receptor-mediated 
signaling pathways to control proliferation, stemness, EMT and tumorigenesis. 
Canonical WNT signaling is activated by Wnt3a ligand, and acts through β-
catenin/TCF transcriptional activity. In the absence of Wnt activation, the so 
called ‘destruction complex’, containing the central scaffold protein Axin, 
adenomatous polyposis coli (APC), and Glycogen-synthase kinase-3 (GSK3) is 
assembled; GSK3 phosphorylates β-catenin and triggers its ubiquitination by 
βTrCP and consequent proteasomal degradation. Upon WNT activation, GSK3 is 
inactivated by phosphorylation, resulting in accumulation and nuclear 
translocation of β-catenin. Besides the canonical WNT signaling, a number of 
non-canonical, β-catenin-independent WNT pathways have been identified with 
the common activity to suppress canonical pathway, and Wnt5a/b are prototype of 
ligands activating these signaling 
139
. Recent works highlighted a deep integration 
of YAP/TAZ in orchestrating canonical and non-canonical WNT responses. 
YAP/TAZ have been demonstrated as integral components of the β-catenin 
destruction complex, which serves as their functional sink. Activation of canonical 
WNT signaling causes rapid release of YAP/TAZ, leading to the activation of 
their transcriptional program. Moreover, YAP/TAZ incorporation in the 
destruction complex is essential for the recruitment of βTrCP and β-catenin 
degradation 
140
. Conversely, in a non-canonical WNT pathway, Wnt5a induces a 
G-protein-mediated inhibition of LATS kinase activity towards YAP/TAZ. In 
turn, the stable YAP/TAZ/TEAD transcription complex drives the transcription of 
secreted factors such as CTGF, Wnt5a and DKK1, which inhibit canonical WNT 
pathway 
137
. 
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1.5.2 Role of YAP/TAZ in cancer 
 
Growing evidence indicates that YAP and TAZ could be involved as key factors 
in different aspects of cancer, including tumorigenesis, metastasis, drug resistance, 
DNA synthesis and repair, control of cyclins for S-phase entry and completion of 
mitosis (Fig. 4) 
141,142
.  
Fig. 4 YAP and TAZ confer aggressive features to cancer cells. Different works highlight the 
role of YAP/TAZ in regulating the development and the sustainment of most solid tumors. Their 
activation promotes cancer stem cell features, proliferation, chemoresistance and metastasis of 
cancer cells.  
Overexpression of YAP/TAZ in normal cells promotes growth factor- and 
anchorage-independent proliferation, EMT and escape from apoptosis 
143
, by 
inducing c-Myc, or by promoting the expression of the Epidermal Growth Factor 
Receptor (EGFR) ligand amphiregulin (AREG) 
127,144
.   
In breast cancer, YAP activation leads to a reduction of epithelial markers, such as 
E-cadherin, and an increase of mesenchymal markers, such as Vimentin and N-
cadherin
143
. In addition, YAP/TAZ regulate several processes important for the 
metastatic spread of cancer, they promote matrix invasion and inhibit cancer cell 
death induced by loss of cell-substrate contact (anoikis)
120
. Knockdown of YAP in 
melanoma cells impairs their ability to invade the matrix, to escape from anoikis 
and produce lung metastasis in xenograft models 
145
. Conversely, overexpression 
of YAP increases the metastatic potential of melanoma and breast cancer cells, 
and this process is highly correlated with YAP-TEAD interaction 
146
.  
It is widely accepted that the growth of solid tumors requires the presence of cells 
with stem cell properties, known as Cancer Stem Cells (CSCs), which initiate and 
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promote tumor development. CSCs are characterized by self-renewal, metastatic 
ability, important chemoresistance and loss of differentiation markers 
120,141
. 
Increasing evidences have shown YAP/TAZ are required and sufficient to endow 
cancer cells of these properties. It has been demonstrated that YAP interacts with 
the transcription factor SRF in breast cancer and promotes the transcription of 
genes typically expressed in mammary stem cells. This YAP-driven stemness 
requires IL-6 upregulation, and the YAP-SRF-IL6 axis is strongly activated in 
basal-like breast cancer, where YAP/TAZ protein levels are inversely correlated 
with patients survival 
147
. Moreover, YAP has been recently demonstrated as a 
critical oncogenic effector of KRAS-induced PC development. In fact, YAP is 
essential for the development of the pre-neoplastic lesions PanIN into pancreatic 
ductal adenocarcinoma (PDAC) in Kras-mutant mice 
148
. In addition, it has been 
shown that YAP is crucial for Kras-independent tumor recurrence in Kras-driven 
models of PDAC 
149
.  
The role of TAZ in conferring stem cell properties has been investigated as well. 
Like YAP, TAZ is necessary for the self-renewal and the tumor-initiation 
capacities of breast cancer. Overexpression of TAZ in non-CSCs endows these 
cells of self-renewal capacity, while silencing of TAZ in patient-derived breast 
cancer stem cell (BCSC) lines reduces their tumorigenic and metastatic potential 
150,151
.  
A main characteristic of CSCs is  the intrinsic resistance to chemotherapy. YAP 
and TAZ have been shown to contribute to this feature. YAP/TAZ upregulation 
confers resistance to several types of anti-cancer drugs, such as anti-tubulin, anti-
metabolite and DNA-damaging agents 
142
.  While TAZ drives the resistance to 
taxol and doxorubicin in breast cancer 
151,152
, YAP activity is correlated with the 
resistance of different cancer cell lines to 5-fluorouracil (5-FU) and its 
overexpression has been shown in therapy resistant colon and esophageal cancers 
153–155
. The molecular mechanisms of YAP/TAZ chemoresistance in cancer cells 
are different and impact on several cellular processes, such as growth factor 
signaling, cell cycle progression, apoptosis, repair of DNA damage and EMT 
142
.  
YAP/TAZ activation promotes the expression of genes involved in the  growth 
factors signaling. In particular in esophageal cancer, YAP induces the expression 
of both EGFR and AREG, thus promoting EGF-independent survival and 
migration of cancer cells through the activation of EGFR signaling pathway 
144
.  
Similarly, YAP is able to induce the insulin-like growth factor (IGF) pathway. It 
has been demonstrated that YAP-dependent IGF2/Akt activation promotes the cell 
survival of medulloblastoma upon irradiation, while the downregulation of IGF2 
reverts this effects 
156
. 
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YAP/TAZ are able to reduce the effect of anti-cancer therapy by promoting cell 
cycle progression even in the presence of DNA damage 
142
. It has been 
demonstrated in different models of PDAC and melanoma that the protein 
complex YAP/TAZ/TEAD cooperates with the transcription factor E2F1 to 
upregulate the expression of cell cycle/mitosis associated genes 
149,157
. The 
consequence of this process is the accumulation of mutations in daughter cells and 
thus genomic instability of cancer cells
142
. 
Cancer cells are able to escape from apoptotic stimuli through YAP activity. YAP 
overexpression protects cancer cells from apoptosis upon chemotherapeutic 
treatment through the induction of anti-apoptotic genes, such as BCL2L1 and 
BIRC5
143,158,159
. Consistently, it has been reported that the development of 
resistance to RAF/MEK inhibitors is correlated with a YAP-dependent increase of 
BCL2L1 expression in several types of tumors 
160
. 
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2. Aims of the study 
 
PC remains one of the most lethal and poorly understood human malignancy. 
Mitogen Activated Protein Kinase (MAPK) pathway is one of the most important 
cascades driving the aggressive features of PC. The activation of MAP3Ks leads 
to the regulation of cellular processes, such as cell cycle progression, adhesion, 
invasion and chemoresistance. Because of its pleiotropic role in PC biology, 
MAP3Ks pathway represents a critical area for the development of novel 
strategies for the treatment of PC. 
 
Specific Aims: 
                  Aim 1 – The role of TAK1 in regulating pancreatic cancer 
aggressiveness and treatment resistance through the activation of YAP/TAZ 
pathways. 
TAK1 plays a central role in the NF-κB activation upon IL1 and TGFβ 
stimulation. Our recent paper has demonstrated that TAK1 orchestrates the 
chemoresistance of PC by sustaining NF-κB activation 57.  
Several studies have demonstrated that the transcriptional cofactors YAP and 
TAZ, the main effectors of the HIPPO pathway, are able to regulate important 
cancer related processes, such as proliferation, tumorigenesis, stemness and drug 
resistance 
161
. In particular, it has been revealed that YAP is a critical oncogenic 
effector of KRAS-induced PC development 
148
.  Although KRAS mutations are 
known to be a driver event for the development of different tumors, increasing 
evidences are accumulating about the development of a KRAS independent 
growth program in KRAS mutated fully competent tumors 
162
. In details, two 
recent papers studied the mechanisms of tumor recurrence after KRAS inhibition 
in pancreatic and lung cancer models, and intriguingly linked the rescue of cell 
survival of initially KRAS addicted tumor cells to YAP1 activation. In genetically 
engineered KRAS
G12D
: Trp53L/+ mouse models, spontaneous relapse of PC 
developed after KRAS
G12D
 inactivation relied on YAP1 overexpression as a 
mechanism for KRAS independent growth 
149,163
. 
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The emerging role of YAP/TAZ in orchestrating the development and the 
sustainment of PC opens the need for the discovery of drugs able to inhibit their 
activities. However, so far, there are no drugs targeting specifically YAP/TAZ and 
the design of drugs, which could target transcriptional cofactors, is challenging.  
 
My hypothesis was that TAK1 drives the aggressive features of pancreatic cancer, 
such as early metastatic behavior and chemoresistance, by sustaining YAP/TAZ 
activity. Inhibiting YAP and TAZ by targeting TAK-1 expression would revert the 
aggressiveness of pancreatic cancer. 
 
 
Aim 2 – The role of MEKK3 in regulating the aggressive features 
of pancreatic cancer. 
MEKK3, or MAP3K3, is a serine/threonine kinase downstream of three different 
receptors, IL1R, TNFαR and TLR8 164, which regulates NF-κB,  JNK and p38 
MAPK pathways 
88,103,104
. 
The role of MEKK3 in regulating embryonic development has been extensively 
studied 
113
. Only recently, the involvement of MEKK3 in driving the development 
and the malignancy of lung, breast and esophageal cancers has been studied 
114–
116
. More in details, MEKK3 is able to regulate both pro-tumoral activities, such 
as proliferation, migration, invasion and chemoresistance, and anti-tumoral 
activity by sustaining the immune response. The clinical relevance of MEKK3 has 
been verified by Hasan et al., who demonstrated that MEKK3 overexpression 
occurs in early stages of esophageal squamous cell carcinoma and, in combination 
with lymph-node positivity, it could be used as a negative prognostic factor for 
this tumor 
116
. The role of MEKK3 in PC and, in particular, the features and the 
pathways regulated by MEKK3 in PC are still unknown. 
My hypothesis was that MEKK3 plays an important role in orchestrating the 
aggressive behavior of pancreatic cancer, by sustaining the activation of both NF-
κB and YAP/TAZ. Targeting of MEKK3 could reverse the intrinsic resistance of 
pancreatic cancer to chemotherapy, as well as its early metastatization. 
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3. Materials and Methods 
 
3.1 Cell Lines and Reagents 
 
Human pancreatic cancer (PC) cell lines AsPc-1, PANC- 1 were purchased from 
the American Type Culture Collection (Manassas, VA). MDAPanc-28 cell line 
was a kind gift by Dr. Paul J. Chiao. Panc1, AsPC1 and MDA-Panc28 PC cell 
lines silenced for the expression of TAK1 were established as described by Melisi 
et al. 
57
. All cell lines used in this study were cultured as monolayers in high 
glucose Dulbecco’s modified Eagle’s medium (DMEM, 41966-029, Life 
Technologies, Gaithersburg, MD), supplemented with 10% heat-inactivated fetal 
bovine serum (FBS, 10270-106, Life Technologies), 2mM L-Glutamine (BE17-
605E, Life Technologies), 100 IU/mL penicillin and 100 μg/mL streptomycin 
(DE17-602E, Life Technologies). Cell lines were grown at 37°C, 5% CO2. 
LYTAK-1 is a orally active TAK-1 kinase selective inhibitor (Ki = 13 nM; p38 Ki 
> 20 mM; IKKb Ki > 20 mM) generously provided by Eli Lilly Pharmaceuticals 
(Indianapolis, IN). For in vitro assays, LYTAK-1 was dissolved in 100% dimethyl 
sulfoxide (DMSO, A3672,0250, AppliChem, Darmstadt, Germany) at a stock 
concentration of 1 mM. The concentration of DMSO did not exceed 0.1% in any 
assay. 
The TAK1 kinase activity was also targeted using (5Z)-7-oxozeaenol TAK1 
kinase selective inhibitor (TOCRIS bioscience, Bristol, UK). For in vitro assays, 
(5Z)-7-oxozeaenol was dissolved in 100% DMSO at a stock concentration of 10 
mM. 
Lithium Chloride (LiCl, L4408-100G, Sigma), a non-specific oral GSK3 inhibitor 
(IC50=10mM) was purchased by AppliChem (Darmstadt, Germany). For in vitro 
assays, LiCl was dissolved in sterile water at a stock concentration of 5M. A 
working concentration of 20mM has been used in all the in vitro assays. 
Gemcitabine (Accord), Oxalipatin (Accord), SN38 (Campto) and Abraxane 
(Celgene) were used at the indicated concentrations for the indicated time. The 
proteasome inhibitor MG132, (Z-Leu-Leu-Leu-al, C2211, Sigma-Aldrich, Saint 
Louis, MO) was dissolved in 100% DMSO and used at a 5µM concentration for 
24h.  
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3.2 Generation of Knock-Out Cell Lines 
 
In order to knock out MEKK3 in Panc1, AsPC1 and MDA-Panc28 PC cell lines, 
cells were transfected with plasmids expressing either control or MEKK3 
targeting guide RNAs , as well as with Cas9-RFP vectors (Transomic, Huntsville, 
AL) using OMNIfect transfection reagent (# OTR1001, Transomic) following 
manufacturer’s instruction. Briefly, one day prior transfection 3,0 x 104 cell were 
seed in 6-wells plate with DMEM 10% FBS without antibiotics. 200 µl of 
transfection solution, containing single guide RNA, Cas9-RFP and  4 µl of 
OMNIfect, were added to each well. 24 hours after transfection, transfected cells 
were selected with 2 µg/ml Blasticidin (A1113902, Life Technologies) for 72 
hours. Cells were then trypsinized, washed with PBS, and re-suspended in DMEM 
with 2mM EDTA (A1104, AppliChem) and 1% penicillin/streptomycin. RFP-
positive cells were single-sorted by FACS (FACS CANTO ARIA II, BD, Franklin 
Lakes, NJ, USA) into 96-well plates in 200 µL of DMEM containing 20% FBS 
and 1% penicillin/streptomycin. Single clones were expanded and screened for 
MEKK3 expression by protein immunoblotting. 
Guide RNA sequences targeting MEKK3 are listed below:  
Gene Clone id Sequence 
MAP3K3 TEVH-1081756 GGACATTCGTGATTTCCGGA 
MAP3K3 TEVH-1148898 CCTTGTGGTGCACAGACACG 
MAP3K3 TEVH-1216040 ACAGACACGTGGTAGCGCCG 
TELG1012 Non targeting 
control 
GGAGCGCACCATCTTCTTCA 
  
 
3.3 Gene Expression Microarrays and 
Pathway Analysis 
 
Total RNA was extracted using Trizol reagent (Life Technologies, Carlsbad, 
California, US) following manufacturer’s instruction. RNA quality was assessed 
by agarose gel electrophoresis. Total RNA was quantified by reading the 
absorbance at 260 nm using a NanoDrop (NanoDrop 2000, Thermo Fisher 
Scientific). Differences in gene expression between control and silenced TAK1 
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cells were examined using Illumina Human 48k gene chips (D-103-0204, 
Illumina, Milan, Italy). Briefly, synthesis of cDNA and biotinylated cRNA was 
performed using the IlluminaTotalPrep RNA Amplification Kit (AMIL1791, 
Ambion), according to the manufacturer’s protocol using 500ng total RNA. 
cRNAs (750 ng) were hybridized using Illumina Human 48k gene chips (Human 
HT-12 V4 BeadChip). Array washing was performed using Illumina High Temp 
Wash Buffer for 10 minutes at 55°C, followed by staining using streptavidin-Cy3 
dyes (Amersham Biosciences, Little Chalfont, United Kingdom). Probe intensity 
data were obtained using the Illumina Genome Studio software (Genome Studio 
V2011.1). Raw data were Loess normalized with the Lumi R package and further 
processed with Excel software. Each microarray experiment was repeated twice. 
Differentially expressed transcripts were tested for network and functional 
interrelatedness using the Ingenuity Pathway Analyses (IPA) software program 
(Ingenuity Systems, Redwood, CA).  
 
3.5 Reverse Transcription PCR and 
quantitative Real Time PCR 
 
Total RNA was extracted using Trizol reagent (Life Technologies) following 
manufacturer’s instruction and quantified using Nanodrop (Thermo Fisher 
Scientific). 1 µg RNA was reverse-transcribed with High Capacity cDNA Reverse 
Transcription Kit (4368814, Applied Biosystems, Foster City, CA, USA) 
following manufacturer’s instruction and 1/10 of the reverse transcription was 
subjected to Real-Time PCR using FAST PowerUp SYBR green mastermix 
(Applied Biosystems, Foster City, CA, USA). The following primers were 
purchased by Life Technologies  and used at 0,2 µM final concentration:   
Primer Sequence 
CTGF Forward  TACCAATGACAACGCCTCCT  
CTGF Reverse   TGCCCTTCTTAATGTTCTCTTCC  
DKK1 Forward  AAAAATGTATCACACCAAAGGACAAG 
DKK1 Reverse   ATCCTGAGGCACAGTCTGATGA 
BDNF forward AGTTCGGCCCAATGAAGAAA 
BDNF Reverse   GAGCATCACCCTGGACGTGTA 
FOSL1 Forward GCAGGCGGAGACTGACAAAC 
FOSL1 Reverse TTCCGGGATTTTGCAGATG 
CYR61 Forward GGATCTGCAGAGCTCAGTCAGA 
CYR61 Reverse CTTTCCCCGTTTTGGTAGATTCT 
AXL Forward TGCGCCAGGGAAATCG 
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AXL Reverse AGGCATACAGTCCATCCAGACA 
YAP Forward CCACAGGCAATGCGGAATAT 
YAP Reverse CTGGCTACGCAGGGCTAACT 
TAZ Forward GGTGCTACAGTGTCCCCACAA 
TAZ Reverse TTTCTCCTGTATCCATCTCATCCA 
Birc3 Forward GACAGGAGTTCATCCGTCAAGTT 
Birc3 Reverse TCTGATGTGGATAGCAGCTGTTC 
Bax Forward TGGAGCTGCAGAGGATGATTG 
Bax Reverse GCTGCCACTCGGAAAAAGAC 
Bcl2 Forward GGCTGGGATGCCTTTGTG 
Bcl2 Reverse CAGCCAGGAGAAATCAAACAGA 
Β-actin Forward GGCATGGGTCAGAAGGATT 
Β-actin Reverse CACACGCAGCTCATTGTAGAAG 
 
Primers for IL1α (QT00001127), IL1β (QT00021385), CXCL1 (QT00199752), 
CXCL2 (QT00013104), CXCL3 (QT00015442) and IL8 (QT00000322) were 
purchased from QIAGEN (Hilden, Germany).  
To quantify the relative changes in gene expression, the 2-ΔΔCT method was used 
and reactions were normalized to endogenous control gene β-actin expression 
levels 
165
. 
 
3.6 Protein extraction and western blotting 
 
Total protein extracts were prepared by lysing cells in radioimmunoprecipitation 
assay buffer (50 mM Tris HCl [pH 8], 150 mM NaCl, 1% Nonidet P-40, 0.5% 
sodium deoxycholate, and 0.1% sodium dodecyl sulfate). All protein extracts were 
quantified by BCA Protein Assay Kit (23225, Thermo Fisher Scientific) and equal 
amounts (20-50 µg of protein extract) were loaded onto SDS-PAGE (8-10%), 
transferred to polyvinylidene fluoride membranes (Immobilon-P, Millipore, 
Billerica, MA, USA) and subjected to immunoblot with the indicated antibodies. 
Antibodies to TAK1 (ab109526, 1:1000), CDH1 (ab40772, 1:10000), ITCH 
(ab109018, 1:1000), TRAF6 (ab94720, 1:1000) Ub-K63 (ab179434, 1:1000) were 
all purchased from Abcam (Cambridge, UK). YAP/TAZ ( sc-101199, 1:1000), 
CTGF (sc-14939, 1:1000), GAPDH (sc-166545, 1:50000) were purchased from 
Santa Cruz Biotechnology (Santa Cruz, CA, USA). MEKK3 (# 5727, 1:1000), 
AXL (# 3269, 1:1000), p65 (# 4764, 1:1000), p-p65 (# 3031, 1:1000), vinculin (# 
13901, 1:1000) were purchased by Cell Signaling (Danvers, MA) and vimentin 
(M 0725, 1:4000) was purchased by DakoCytomation (Glostrup, Denmark). 
Secondary anti-mouse and anti-rabbit antibodies were purchased from Santa Cruz 
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Biotechnology (Santa Cruz, CA, USA). All antibodies were diluted in 3% Non-fat 
dry milk dissolved in  Tris Buffered Saline (TBS) or 5% bovine serum 
albumin/TBS/0.1% Tween-20. Immunoreactive proteins were visualized with 
Immobilion Western kit (EMD Millipore) according to the manufacturer’s 
instructions. Images were acquired using ImageQuant LAS 4000 mini (GE 
Healthcare Life Sciences, Little Chalfont, UK). 
 
 
3.7 Transwell migration and Wound healing 
assays 
 
Cells were detached and counted. 5 × 10
4
 cells, in a volume of 100 µl DMEM 
containing 0,1% FBS, were seeded in the upper chamber while the bottom 
chamber of the transwell was filled with 600 µl of DMEM with 10% FBS. Either 
LiCl or NaCl (control) was added to the upper chamber at a 20mM concentration . 
Cells were allowed to migrate for 20 hours. Then cells remaining in the upper 
chamber were scrubbed away with a cotton pad and cells remaining on the bottom 
layer of the upper chamber were subjected to DAPI staining as follows: the upper 
chamber was washed twice with PBS and then cells were fixed with 4% 
formaldehyde for 20 minutes, permeabilized with 0,2% Triton for 25 minutes and, 
after being washed with PBS, they were stained with 5 µM DAPI for 5 minutes. 
Each membrane was scanned by fluorescence microscopy (EVOS FL Auto, 
Thermo Fisher Scientific) and all the cells were automatically counted using 
ImageJ software. Each sample was assayed in triplicate. Graphs show percentage 
of cells relative to control. Student t-test has been used to calculate p-values. 
Wound Healing assay was performed as described below. PC cell models were 
seed at a density of 6.0 × 10
5
 in a 6-well plates. After 24 hours, a straight scratch 
was made using a pipette tip to simulate a wound. The cells were washed gently 
with cold phosphate-buffered saline (PBS) and rinsed with fresh complete 
medium. Photographs of at least three different points were taken immediately and 
every hour for the following 72 hours by automatic microscopy (EVOS FL Auto, 
Thermo Fisher Scientific). The Wound healing tool plugin has been used to 
measure wound opening. 
 
33 
 
3.8 Cell Proliferation assays 
 
Control or MEKK3 KO PC cell lines were seeded at a density of 1.0 × 10
3
 
cells/well in 96-well plates. Cell proliferation was measured by using the 
Sulforhodamine B (SRB) assay. At specific time points (0, 24, 48 and 72 hours), 
cells were washed with PBS and fixed with 50% Trichloracetic acid solution in 
water. Following incubation for 1 hour at 4°C, cells were washed three times with 
distilled water and labeled with a solution of 0,4% SRB/1% acetic acid for 30 
minutes. Labelled cells have been washed three times with 1% acetic acid solution 
and SRB was dissolved by adding 10mM TrisHCl pH 10,5. Assorbance at 540nm 
has been measured using the iMark microplate reader (Bio-rad, Hercules, CA, 
USA). Fold increase proliferation has been calculated by dividing the absorbance 
measured at 24, 48 and 72 hours by the absorbance measured at T0.  
 
3.9 Nude Mouse Orthotopic Xenograft Models 
 
5-weeks old female athymic nude mice (Crl:CD1-Foxn1nu, CDNSSFE05S) were 
purchased from Charles River (Wilmington, MA, USA). All mice were housed 
and treated in accordance with the guidelines of The University of Verona Animal 
Ethic Committee, and maintained in specific pathogen-free conditions.  To 
produce pancreatic tumors, PC cells were harvested from subconfluent cultures by 
brief exposure to 0.05% trypsin-EDTA (GIBCO, ref 25300-054, Life 
Technologies). Trypsin activity was quenched with medium containing 10% fetal 
bovine serum and tumor cells were resuspended in a solution of 1:1 Matrigel:PBS 
at 1.0 x 10
4
 cells/µl concentration (Matrigel Matrix Growth Factor, 356230, BD, 
Franklin Lakes, NJ). Orthotopic injection of PC cells was performed as described 
below. Mice were anesthetized with a 3% isoflurane–air mixture. A small incision 
in the left abdominal flank was made, and the spleen was exteriorized. 5 x 10
5
 
tumor cells in 50 µl were injected subcapsularly in a region of the pancreas just 
beneath the spleen. A 30-gauge needle and 1 mL disposable syringe were used to 
inject the tumor cell suspension. A successful subcapsular intrapancreatic 
injection of tumor cells was identified by the appearance of a fluid bleb without 
intraperitoneal leakage. To prevent such leakage, a cotton swab was held over the 
injection site for 1 minute. One layer of the abdominal wound was closed with 
wound clips (Auto-clip; Clay Adams, Parsippany, NJ). Tumor growth was 
monitored by either bioluminescence with D-Luciferine Firefly (Part Number. 
#122799, PerkinElmer, Boston, MA) or fluorescence imaging performed using a 
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cryogenically cooled IVIS 100 imaging system coupled with a data-acquisition 
computer running the Living Image software program (Xenogen). 
 
 
3.10 Colony-forming assay 
 
5 x 10
2
 cells were seeded in 6-wells plates and grown for 15 days. To maintain 
good growth conditions, the medium was changed every 48 hours. Cells were 
stained for 30 minutes with 0,1% crystal violet dissolved in 10% of formaldehyde. 
Cells were washed three times with water and colonies were counted by automatic 
microscopy (EVOS FL Auto, Thermo Fisher Scientific). 
 
3.12 Chromatin Immunoprecipitation (ChIP) 
assay 
 
Cells were crosslinked and chromatin was extracted and sonicated. Chromatin was 
incubated overnight with the following antibodies: IgG (Vector Laboratories, 
X0720, 1:50), anti-Phospho-NF-kB (#3033, 1:50), anti-Acetyl-H3 K9/K14 (Cell 
Signaling, #9677, 1:50), anti-YAP (Santa Cruz Biotechnology, sc-101199, 1µg). 
Dynabeads Protein G were blocked overnight with 1mg/ml Sonicated Salmon 
Sperm (Thermo Fisher Scientific, 15632011) and 1mg/ml Bovine Serum Albumin 
(Thermo Fisher Scientific, AM2616). 30µl Dynabeads Protein G (50% slurry) 
were used for each IP. Immunpecipitated chromatin was purified with DNeasy 
Blood & Tissue Kit (Qiagen, 69504) following manufacturer’s instruction. 
Quantitative Real Time PCR was used to assess for DNA enrichment using FAST 
PowerUp SYBR green mastermix (Applied Biosystems). Immunoprecipitated 
chromatin was normalized to input chromatin (GAPDH gene). Values shown in 
the histograms have been normalized to IgG. 
The following primer sequences were used: 
Primer Sequence 
AXL Forward GAGTGGAGTTCTGGAGGAATGTTT 
AXL Reverse GTGAGGCCGTGTCTCTCTATCC 
DKK1 Forward GCACCCAAGTTCCCAGAGTTC 
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DKK1 Reverse CGAGCGTTATAGCAGACGACTTT 
CTGF Forward GCCATATTCAACATCTGCACACA 
CTGF Reverse TGAGGTCAGGACAAGGAAAGAATAG 
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4. Results and Discussions 
 
4.1 Aim 1 - To determine the role of TAK1 in PC 
aggressiveness and treatment resistance through the 
activation of YAP/TAZ. 
 
4.1.1 Silencing of TAK1 affects the HIPPO pathway. 
In order to identify TAK1-regulated pathways, we used AsPC1, Panc1 and MDA-
Panc28 PC cell lines previously transduced  with  lentivirus expressing TAK1-
specific shRNA or scramble sequence as a control 
57
.  We compared gene 
expression profiles between TAK1-silenced and  control cell lines by genome-
wide differential gene expression analyses.  Upon TAK1 silencing, we observed a 
deregulation of several pathways, including autophagy, WNT and HIPPO 
pathways. In particular, we identified a significant reduction in the expression of 
genes upregulated by the Hippo pathway, such as DKK1, CTGF, AXL (Fig. 5A). 
We validated our microarray data by quantitative Real Time (qRT) PCR and we 
measured a significant reduction of DKK1, CTGF and AXL expression in TAK1-
silenced cells as compared to their controls (Fig.5B).  
Hippo 
WNT 
Autophagy 
A) 
B) 
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Fig. 5 TAK1 silencing affects different pathways in PC cell lines. A) Heatmap of 
TAK1-regulated pathways. The identification of relevant biological processes and genes was 
assessed by global transcript profiling. Signaling pathways enriched among genes 
differentially expressed in TAK1 silenced cell lines versus their respective controls were 
analysed. Gene expression levels and unsupervised hierarchical clustering of differentially 
expressed genes were performed. The log2of the gene expression levels are shown as colour-
code heat map (green = decreased expression, red = increased expression). B) Expression of 
DKK1, CTGF and AXL in our TAK1 models. Histograms show the fold change in RNA 
expression between the gene of interest and β-actin as assessed by qRT-PCR. Mean values 
and SD from 2 independent experiments conducted in triplicate are shown. T-test has been 
used to perform statistical analysis. 
 
 
 
4.1.2 TAK1 silencing decreases YAP/TAZ protein levels. 
 
To further study the regulation of the HIPPO pathway by TAK1, we evaluated the 
expression of both YAP/TAZ and their regulated genes in PC cell lines stably 
interfered for TAK1 .We observed a strong decrease of YAP/TAZ protein levels 
in TAK1 silenced cells as compared to control cells (Fig.6A). Conversely, we 
could not detect any significant reduction in YAP and TAZ mRNA levels 
(Fig.6B). To corroborate our finding that the downregulation of YAP and TAZ 
proteins caused a reduction of their target genes DKK1, CTGF and AXL (Fig. 
5B), we assessed CTGF protein levels by Western blot as well.  We observed a 
strong decrease of CTGF in all shTAK1 cell lines as compared to their controls 
(Fig.6C). 
To better evaluate whether YAP/TAZ reduction could be due to shRNA off-target 
effects or to a remodeling of cellular shape, previously reported  as a consequence 
of TAK1 silencing 
57
, we transiently silenced the expression of TAK1 in AsPC1, 
Panc1 and MDA-Panc28 cells by using predesigned siRNA against TAK1. As 
early as 72 hours post transfection, when no change in cell shape could be 
detected, we observed a significant reduction of YAP/TAZ protein levels in PC 
cell lines (Fig. 6D), ruling out the possibility that reduction of YAP/TAZ protein 
levels could be due to a long-term adaptive effect of TAK1 silencing.  
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Fig. 6 TAK1 silencing reduces YAP/TAZ protein levels. A) Cell extracts from ASPC1, PANC1 
e MDA-PANC28 control and shTAK1 cells were subjected to immunoblot with the indicated 
antibodies. All signals were normalized to γ-tubulin and densitometric analysis is shown below 
each immunoblot. B) qRT-PCR analysis of YAP/TAZ mRNA in ASPC1, PANC1 e MDA-
PANC28 control and shTAK1 cells. Histograms  show the fold change in RNA expression 
between the gene of interest and β-actin. Mean values and SEM from one independent experiment 
conducted in triplicate are shown.  C) Cell extracts from ASPC1, PANC1 e MDA-PANC28 
control and shTAK1 cells were subjected to immunoblot with the indicated antibodies. All signals 
were normalized to γ-tubulin and densitometric analysis is shown below each immunoblot. D) Cell 
extracts from ASPC1, PANC1 e MDA-PANC28 cells transiently transfected with either control or 
TAK1-targeting siRNA were subjected to immunoblot with the indicated antibodies.  
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4.1.3 TAK1 kinase activity is not involved in YAP/TAZ regulation. 
 
In order to identify the mechanisms by which TAK1 regulates the YAP/TAZ 
protein levels, we first evaluated whether the reduction of YAP/TAZ could be 
related to TAK1 kinase activity. To this aim, we treated for 72 hours AsPc-1, 
PANC-1, and MDAPanc-28 cell lines with increasing doses of two TAK1 
selective inhibitors, 5Z-7-oxozeaenol (2,5 and 5 µM) and LYTAK1 (5 and 10 
nM). We observed that the pharmacological inhibition of TAK1 did not affect 
YAP/TAZ protein levels in any tested PC cell line (Fig. 7), suggesting that their 
levels depend on the presence of TAK1 rather than its kinase activity. 
 
 
Fig. 7 TAK1 kinase activity did not regulate YAP/TAZ protein levels.  Cell extracts from 
ASPC1, PANC1 e MDA-PANC28 cell lines treated with 5,7-Z-oxozeaenol (2,5uM and 5uM) and 
(5Z)-7-Oxozeaenol (mM) 
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LY26 (5nM and 10nM) for 72 hours were subjected to immunoblot with the indicated antibodies. 
All signals were normalized to vinculin. 
 
In order to study whether TAK1 is able to protect YAP and TAZ from 
proteasomal degradation, we treated TAK1 silenced and control cells with the 
well-known proteasome inhibitor MG132. Interestingly, upon MG132 treatment 
we observed an increase of YAP and TAZ protein levels that was more significant 
in TAK1 silenced cells than in control cells. In particular, TAZ protein levels 
increased 19.87, 35.83 and 9.93 fold in shTAK1 AsPC1, Panc1 and MDA-Panc28 
respectively (Fig. 8A). These data suggest that TAK1 could somehow protect 
YAP and TAZ from proteasomal degradation. In order to investigate the role of 
TAK1 in modulating K63- or K48-linked poly-ubiquitination, we analyzed the 
expression of TRAF6 and ITCH in TAK1 silenced cells. Interestingly, we 
observed an increase of ITCH protein, which mediates K48-linked 
polyubiquitination, and a reduction of TRAF6, that mediates K63-linked 
polyubiquitination, in shTAK1 AsPC1, Panc1 and MDA-Panc28 cell lines (Fig. 
8B). Accordingly, we also revealed an important decrease of K63-linked poly-
ubiquitinated proteins in TAK1 silenced cells as compared to their controls (Fig. 
8C).  
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Fig. 8 TAK1 regulates YAP/TAZ proteasomal degradation. A) YAP/TAZ protein levels in 
ASPC1, Panc1 e MDA-Panc28 treated with MG132. AsPC1, Panc1 and MDA-Panc28 cell lines 
were treated with 5uM MG132  for 24h. Cellular extracts were subjected to immunoblot with the 
indicated antibodies. B-C) Cellular extracts from Panc1, AsPC1 and MDA-Panc28 control and 
shTAK1 cells were subjected to immunoblot with antibodies against ITCH and TRAF6 (B) and 
anti-K63-linked ubiquitin (C).  
 
 
4.1.4 Targeting GSK3α activity downregulates both TAK1 and 
YAP/TAZ pathway. 
 
The emerging role of YAP/TAZ in orchestrating the development and the 
sustainment of PC opens the need for the discovery of drugs to inhibit their 
activities 
148,149. However, so far, there are no drugs targeting specifically 
YAP/TAZ and the design of drugs which could target transcriptional cofactors is 
challenging. As previously demonstrated, the well known TAK1 kinase inhibitors, 
5,7-Z-oxozeaenol and LY26, are not able to reduce YAP/TAZ protein levels in PC 
cells, thus they can not be used in the clinics to modulate YAP/TAZ activities. 
Bang et al. have shown that inhibition of GSK3α affects the stability of TAK1 166. 
In light of this work, we asked whether GSK3α could regulate both the YAP/TAZ 
pathway and the aggressive features of PC by inhibiting TAK1.  
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We observed a decrease of both TAK1 and YAP/TAZ protein levels in AsPC1 
and Panc1 PC cell lines, following inhibition of GSK3 activity with 20 mM 
LiCl. A higher LiCl concentration, such as 50mM, was needed to reduce TAK1 
and YAP/TAZ protein levels in MDA-Panc28 cells (Fig. 9A). Like in TAK1 
silenced cells, the decrease of TAK1 and YAP/TAZ proteins is not correlated with 
a reduction of their mRNA levels upon LiCl treatment (Fig. 9B). Because LiCl 
has several off target effects, we tested two more specific GSK3α inhibitors in PC 
cells, CHIR-99021 and LY2090314.  Following treatment of AsPC1, Panc1 and 
MDA-Panc28 with 3 µM CHIR or LY2090314 for 72 hours, we observed a 
different reduction of YAP/TAZ and TAK1 protein levels (Fig. 9C), which was 
not correlated to a reduction of their mRNA (Fig. 9D, E). In particular, upon 
treatment with LY2090314, we observed a more prominent decrease of YAP in 
both AsPC1 and MDA-Panc28 cells, while only TAZ was downregulated in 
Panc1 cells (Fig. 9C). 
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Fig 9. GSK3α inhibition reduces TAK1 and YAP/TAZ protein levels. A) Cellular extracts from 
Panc1, AsPC1 and MDA-Panc28 cells treated with 20, 30 and 50 mM LiCl for 72h were subjected 
to Western blot analysis for the expression of YAP/TAZ and TAK1.  B) TAK1 and YAP/TAZ 
genes expression levels in Panc1, AsPC1 and Panc28 cells treated with 20mM LiCl  for 72h were 
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evaluated by qRT-PCR. Histograms show mRNA levels of the indicated target genes over β-actin. 
Mean values and SD are shown. C) Cellular extracts from AsPC1, Panc1 and MDA-Panc28 cells 
treated with 3uM CHIR-99021 or LY2090314 for 72h were subjected to Western blot analysis for 
the expression of YAP/TAZ, TAK1. D-E) TAK1 and YAP/TAZ genes expression levels in Panc1, 
AsPC1 and Panc28 cells treated with 3 µM LY2090314 (D) or CHIR99021 (E) for 72h were 
evaluated by qRT-PCR. Histograms show mRNA levels of the indicated target genes over β-actin. 
Mean values and SD are shown. 
 
To further investigate whether GSK3 inhibition could impair the YAP/TAZ 
pathway, we measured the expression of YAP/TAZ target genes such as CTGF, 
AXL, DKK1 and CYR61. In details, upon treatment with LiCl, we observed a 
0,59 (p<0,001) and 0,47 (p<0,001) fold reduction in AsPC1 and MDA-Panc28 in 
CTGF expression, which is not significantly downregulated in Panc1 cell lines; 
AXL was downregulated 0,65 fold (p<0.05)  in AsPC1, but not in Panc1 and 
MDA-Panc28 cell lines; CYR61 was reduced 0.63 fold (p<0.05)  in AsPC1 cells, 
but not in Panc1 and MDA-Panc28 cell lines. Better results have been obtained by 
inhibiting GSK3 with LY2090314 and CHIR99021. In details, upon treatment 
with LY2090314 and CHIR99021, we measured a significant downregulation of 
CTGF, AXL, DKK1 and CYR61 expression in PC cell lines (Fig. 10) as reported 
in the table below. As shown, the treatments affect in different ways the 
expression of YAP/TAZ target genes in AsPC1, Panc1 and MDA-Panc28. This 
effect could be related to the different genetic background of PC cell lines, in 
which several mutations could drive the response to the treatment. 
 
 
Table 1. Differential expression levels of YAP/TAZ target genes in AsPC1, Panc1 and MDA-
Panc28 treated or not with LY2090314 and CHIR99021. 
 
 
 
 
 
 
  AsPC1 Panc1 MDA-
Panc28 
 
LY2090314/DMSO 
CTGF 0.08 ± 0.15 0.26 ± 0.23 0.23 ± 0.08 
AXL 0.18 ± 0.14 0.12 ± 0.22 0.45 ± 0.09 
DKK1 1.02 ± 0.14 3.47 ± 0.22 0.99 ± 0.08 
CYR61 0.44 ± 0.14 1.20 ± 0.22 0.23 ± 0.08 
 
CHIR99021/DMSO 
CTGF 0.18 ± 0.2 0.17 ± 0.14 0.33 ± 0.07 
AXL 0.25 ± 0.19 0.20 ± 0.13 0.46 ± 0.07 
DKK1 0.46 ± 0.19 0.53 ± 0.12 0.95 ± 0.06 
CYR61 0.33 ± 0.19 0.53 ± 0.14 0.29 ± 0.07 
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Fig 10. GSK3α inhibition affects YAP/TAZ-target genes expression.  The expression of 
YAP/TAZ target genes was assessed by qRT-PCR in Panc1, AsPC1 and Panc28 cells treated with 
LiCl (20mM), LY2090314 (3µM) or CHIR99021 (3µM) for 72h. Histograms show mRNA levels 
of the indicated target genes over β-actin. Mean values and SD are shown from one experiment 
conducted in triplicate are shown. ***, P < 0.001; **,P<0.01; *, P <0,05, by t-test.  
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Because the YAP/TAZ pathway regulates several processes involved in tumor 
malignancy, we investigated whether GSK3 inhibition was correlated with a 
reduction of migration, proliferation and stemness of PC cells. Treatment of PC 
cells with 20 mM LiCl caused an strong reduction in their migration ability, 
amounting to 46% and 64% inhibition in AsPC1 and Panc1 respectively, as 
assessed by transwell migration assays (Fig. 11A). We also measured an 
important reduction of proliferation in PC cells treated with LiCl (20 mM). More 
in details, LiCl inhibited proliferation by 27% for AsPC1 (p<0,001), 12% for 
Panc1 (p<0,001) and 40% for MDA-Panc28 (p<0,001) respectively, as compared 
to untreated cells (Fig. 11B). Better results have been obtained by inhibiting 
GSK3 with LY2090314 and CHIR99021. In details, upon treatment with 
LY2090314, we measured a significant reduction of proliferation equal to 50.78% 
(p<0,001), 69.5% (p<0,001) and 30.47% (p<0,001) for AsPC1, Panc1 and MDA-
Panc28, respectively. Likewise, upon treatment with CHIR99021, we observed a 
reduction in proliferation of 30.89% (p<0,001), 32.25% (p<0,001) and 18.98% 
(p<0,01) for AsPC1, Panc1 and MDA-Panc28, respectively. We could 
hypothesize that the decrease of TAZ in Panc1 cells following LY2090314 could 
account for a slightly more pronounced inhibition of proliferation (Fig. 11B). 
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Fig 11. GSK3α inhibition impairs migration and proliferation of PC cells. A) A 
transwell assay was performed in AsPC1, Panc1 and MDA-Panc28 treated with 20 mM 
of LiCl for 24h. Images show the migrated cells. Histograms show the number of 
migrated cells. Mean and SD are indicated. B-C) Graphs show the results of cell proliferation 
assays in Panc1, AsPC1 and MDA-Panc28 treated or not with 20 mM LiCl (B), 3 µM CHIR99021 
and 3 µM LY2090314 (C). Measurements were conducted in octuplicate. Mean values and SD are 
shown from one experiment conducted in octuplicate are shown. ***, P < 0.001; **,P<0.01, by t-
test.   
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4.1.5 Aim 1 – Discussion 
 
PC is one of the most lethal human cancers and will continue to be a major 
unsolved health problem in the 21st century. One of the major challenges remains 
in developing effective therapeutic strategies that target the unique molecular 
biology of PC and to integrate these molecularly targeted agents into established 
combination chemotherapy regimens in order to improve patients survival. In this 
work we demonstrated a unique role for TAK-1 in the sustainment of YAP and 
TAZ.  
TAK1 has recently emerged as a central regulator of diverse physiological 
processes including development, metabolism and immune and stress responses, 
leading to the activation of the transcription factors NF-κB and AP-1 41. The role 
of TAK1 in PC has been recently demonstrated 
57
. Silencing or pharmacological 
inhibition of TAK1 reduces NF-κB activation, thereby strongly potentiating the 
activity of commonly used chemotherapeutic agents in PC cell lines 
57
.  
Several studies have demonstrated that the transcriptional cofactors YAP and 
TAZ, the main effectors of the HIPPO pathway, are able to regulate important 
cancer related processes, such as proliferation, tumorigenesis, stemness and drug 
resistance 
161
. In particular, it has been shown that YAP is essential for the 
development of PC in KRAS mutated mice, it drives EMT and promotes the 
tumor growth of PC even upon KRAS inactivation 
148,149,163
 . The emerging role of 
YAP/TAZ in orchestrating the development and the sustainment of PC opens the 
need for the discovery of drugs able to inhibit their activities. However, so far, 
there are no drugs targeting specifically YAP/TAZ and the identification of new 
molecules, which could target these transcriptional cofactors, is challenging.  
To our knowledge, our present study is the first to identify TAK1 as a regulator of 
YAP/TAZ. In this regard, we demonstrated that silencing of TAK1 induced a 
significant downregulation of the HIPPO pathway (Fig.5A) and, in particular, a 
reduction in the expression of YAP/TAZ target genes DKK1, CTGF and AXL 
(Fig. 5B). Interestingly, we observed that silencing of TAK1 was correlated to a 
strong decrease in YAP/TAZ protein levels, but not to a downregulation of 
YAP/TAZ mRNA levels in PC cells (Fig. 6 A,B). In order to identify the 
mechanisms by which TAK1 could regulate the stability of YAP/TAZ, we 
evaluated whether TAK1 kinase activity was involved in this process. 
Interestingly, we observed that treatment with two TAK1 kinase inhibitors did not 
affect YAP/TAZ protein levels (Fig. 7), suggesting that TAK1 kinase activity was 
not involved in YAP/TAZ stabilization. Thus, we investigated whether 
proteasomal degradation was involved in YAP/TAZ degradation. Treatment with 
the proteasome inhibitor, MG132, led to an increase of TAZ protein levels that 
was stronger in shTAK1 cells than in their controls (Fig. 8A), suggesting that 
ubiquitination processes are involved in YAP/TAZ stabilization. Different kinds 
of ubiquitination exist and, in particular, K48-linked polyubiquitination mediates 
the proteasomal degradation of proteins, while K68-linked polyubiquitination 
prevents it 
167,168
. Different studies have demonstrated that two important E3 
ubiquitin ligases, ITCH and TRAF6, interact with and regulate TAK1 
169
. In 
particular, upon IL1 stimulation, TRAF6 binds to and promotes the activation of 
TAK1 by mediating its K63-linked poly-ubiquitination 
43
. On the contrary, in 
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combination with CYLD, ITCH induces K48-linked poly-ubiquitination of TAK1 
thereby inhibiting its activity 
41
. Thus, we hypothesized that ITCH and TRAF6 
could regulate YAP/TAZ degradation in PC cells. Interestingly, we observed a 
significant increase of ITCH and a reduction of TRAF6 in PC cells upon silencing 
of TAK1 (Fig. 8B), which was correlated to a strong decrease of total TRAF6-
mediated K63-linked poly-ubiquitination in shTAK1 cells (Fig. 8C). Altogether, 
these data demonstrate for the first time that TAK1 regulates the proteasomal 
degradation of YAP/TAZ independently of its kinase activity, by modulating 
ITCH and TRAF6 expression.  
In order to target YAP/TAZ activity by modulating TAK1 expression, we took 
advantage of a recent paper demonstrating that targeting GSK3α activity could 
affect TAK1 stability 
166
. We observed for the first time that inhibition of GSK3 
was correlated to a significant reduction of both TAK1 and YAP/TAZ protein 
levels in PC cells (Fig. 9 A, C). Like in shTAK1 cells, we did not measure any 
decrease in YAP/TAZ mRNA levels (Fig 9 B, D, E), but we observed an 
important downregulation of YAP/TAZ target genes upon GSK3 inhibition that 
was stronger upon LY2090314 treatment rather than CHIR99021 or LiCl treatments 
(Fig. 10). This diffenent effect on YAP/TAZ-regulated genes observed could be related 
to the diverse genetic background of PC cell lines, in which several mutations could drive 
the response to the treatment. These data further highlight that the presence of TAK1 
is essential for YAP/TAZ stabilization rather than for their expression.   
GSK3α/β are two of the main kinases regulated by canonical WNT pathway 139. 
Recent works highlighted the role of canonical and non-canonical WNT pathways 
in regulating YAP/TAZ stability and activity. Azzolin et al. demonstrated that 
YAP/TAZ are integral components of the β-catenin destruction complex 140. 
Activation of the canonical WNT pathway induces the recruitment of AXIN/β-
catenin/YAP/TAZ complex to Low Density Lipoprotein Receptor-related Protein 
6 (LRP6). This interaction induces a rapid release of YAP/TAZ from the complex, 
leading to their nuclear translocation and activation of YAP/TAZ/TEAD-
dependent transcription. In the absence of WNT activation, YAP/TAZ drive the 
recruitment of the β-Transducin repeat Containing E3 ubiquitin Protein ligase 
(βTrCP) to AXIN/β-catenin/YAP/TAZ complex, thereby regulating the 
degradation of both YAP/TAZ and β-catenin. This work identifies the canonical 
WNT pathway and, in particular, the β-catenin destruction complex as the 
functional sink which mediates the degradation of both YAP/TAZ and β-catenin 
proteins 
140
. Conversely, Park et al. demonstrated the role of non-canonical WNT 
pathway in regulating YAP/TAZ activity 
137
. The stimulation of non-canonical 
WNT pathway mediated by Wnt5a/b induces the activation of Gα12/13 proteins. 
The consequently activated phosphorylation cascade culminates in the inhibition 
of LATS and in the stabilization of YAP/TAZ. In turn, YAP/TAZ translocate into 
the nucleus where they regulate the expression of different secreted factors, such 
as DKK1, which can inhibit canonical WNT pathway. This work demonstrated 
that YAP/TAZ regulation by the non-canonical WNT pathway is independent on 
the destruction complex 
137
.  
Different studies demonstrated a role for TAK1 in mediating non-canonical WNT 
signaling. Wnt1 stimulation resulted in autophosphorylation and activation of 
TAK1 in a TAB1-dependent fashion, resulting in the stimulation of a Nemo-like 
kinase (NLK)-MAPK cascade and in an inhibitory phosphorylation of TCF/LEF 
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170,171
. The TAK1-NLK-MAPK cascade could be also activated by the non-
canonical Wnt5a/Ca2+ pathway to counteract canonical β-catenin signaling. 
However, a kinase-inactive mutant of TAK1(K63W) only minimally reversed  the 
blocking effect of Wnt5a on β-catenin activation 172, suggesting that other TAK1-
regulated mechanisms could affect the canonical WNT pathway. Our data identify 
the mechanism by which TAK1 promotes YAP/TAZ stabilization and impacts on 
the canonical WNT pathway. 
Interestingly, GSK3 inhibition, which simulates the activation of the canonical 
WNT pathway, induced a strong decrease in YAP/TAZ protein levels by 
modulating TAK1 expression (Fig. 9). We speculate that non-canonical 
137
 and 
canonical 
140
 WNT pathways can regulate the fate of YAP/TAZ by modulating 
TAK1. 
Our study demonstrated for the first time that pharmacological silencing of TAK1, 
mediated by GSK3 inhibition, downregulates the YAP/TAZ pathway in PC cells. 
In order to investigate the biological relevance of this phenomenon, we evaluated 
the effect of GSK3-mediated YAP/TAZ dowregulation on different aspects of PC 
cells. 
 We observed that treatment with GSK3 inhibitors led to a significant reduction in 
proliferation and migration of cancer cells, that was more evident upon LY2090314 
rather than LiCl or CHIR99021 treatment (Fig. 11). Similar results have been 
reported in two different papers. Marchand et al. demonstrated that silencing of 
GSK3 impaired the anchorage-independent tumor growth of PC cells 
174
, while 
Ying et al. identified in GSK3β one of the main players that drive the invasion of 
PC cells 
173,174
. Additional studies will be necessary to evaluate the effects of 
TAK1 pharmacological silencing on YAP/TAZ-regulated oncogenic features, 
such as stemness, metastatization and drug resistance, in both in vitro and in vivo 
experiments.    
The past two decades have witnessed a major focusing of PC research on several 
molecules that are high in the signal transduction cascade, with a particular 
interest in membrane receptors such as the EGFR 
175
. From the results of the 
clinical trials with inhibitors of this molecule in PC we learned that the single 
mutation of K-Ras - the most common genetic alteration in PC - is probably able 
to inactivate the antitumor activity of anti-EGFR approaches 
176
. On the other 
hand, the design of drugs which could target transcriptional factors and cofactors, 
such as NF-kB and YAP/TAZ, is challenging. We believe that the 
pharmacological silencing of TAK1 could represent a better approach to reduce 
the aggressive behavior of PC. We concluded by observing that TAK1 is not a 
single enzyme, but it may be consider rather as the active component of a large 
protein signaling complex, characterized by different proteins, such as YAP and 
TAZ, and involved in the regulation of several signaling pathways. 
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4.2 Aim 2 - To determine the role of Mitogen-Activated 
Protein Kinase Kinase Kinase 3 (MAP3K3 or MEKK3) in 
the metastatic behavior of PC. 
 
4.2.1 Knock-out of MEKK3 reverts EMT features in pancreatic 
cancer cells. 
In order to study the role of MEKK3 in the metastatic behavior of PC, we 
established MEKK3 Knocked-Out (KO) cells by using CRISPR-Cas9 in Panc1, 
AsPC1 and MDA-Panc28. These cell lines were transfected with vectors 
expressing  MEKK3-specific gRNA or control gRNA in combination with the 
DNA endonuclease, Cas9, which resulted in MEKK3 KO (Fig. 12B).  
To determine the effect of MEKK3 KO on different EMT features, we evaluated 
both the expression of epithelial and mesenchymal markers and the migration of 
MEKK3 KO and control cell lines. We demonstrated that MEKK3 KO promotes 
the expression of the epithelial marker E-cadherin, and partially reverts the 
expression of the mesenchymal marker Vimentin, in all the three PC cell lines 
under study(Fig. 12B). Moreover, we observed that MEKK3 KO reduced the 
migratory abilities of Panc1 and AsPC1 by wound healing assay (Fig. 12C). 
Together, these data demonstrate that MEKK3 triggers EMT and migration in PC 
cells.  
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Fig.12 MEKK3 knock-out reverts EMT features in Panc1 and AsPC1 cell lines. A,B) 
Assessment of MEKK3 knock-out in Panc1, AsPC1, MDA-Panc28 cell lines. Cellular extracts 
from Panc1, AsPC1 and MDA-Panc28 cells wild-type or KO for MEKK3 were subjected to 
Western blot analysis with antibodies against MEKK3 (A), CDH1 and VIM (B). C) A scratch 
was performed in control and MEKK3 KO cells. Images show a time course of wound 
closure. Histograms show percentage wound closure. Mean and SD are indicated.  
 
 
4.2.2 MEKK3 KO reduces proliferation and stemness of 
pancreatic cancer cells in in vitro experiments. 
 
Aberrant proliferation and stemness are important features of cancer cells. 
In order to study the role of MEKK3 in orchestrating these processes, we first 
evaluated whether knocking-out MEKK3 impaired cell proliferation. We 
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observed that MEKK3 KO reduces cell proliferation at 72 hours by 22% in 
AsPC1 and 32% in MDA-Panc28 in comparison with their controls, while we 
did not observe any decrease in Panc1 cells (Fig. 13A). Then, we carried out 
colony formation assays in MEKK3 KO or control Panc1, AsPC1 and MDA-
Panc28 cells and we observed a significant decrease in colonies size in 
MEKK3 KO cells. In details, MEKK3 KO induced 2,5, 2,07 and 1,8 fold 
reduction in colony size (p<0,0001) in Panc1, AsPC1 and MDA-Panc28, 
respectively (Fig.13B). These data demonstrate that MEKK3 is a major 
regulator of proliferation and stemness of PC cells.  
 
 Panc1 Ctrl 
Panc1 MEKK3 KO 
Colonies size 2300 ± 98 900 ± 15 
Fold decreased 1 2.5 
   
 AsPC1 Ctrl AsPC1 MEKK3 KO 
Colonies size 999± 19.8 482 ± 20.6 
Fold decreased 1 2.07 
   
 MDA-Panc28 Ctrl MDA-Panc28 MEKK3 KO 
Colonies size 807± 12 447 ± 6.71 
Fold decreased 1 1.8 
 
Fig 13. MEKK3 knocked-out impairs on proliferation and stemness  of PC cells. A) 
MEKK3 KO affects proliferation of PC cell lines. Cell proliferation assays in Panc1, 
AsPC1 and MDA-Panc28 control and MEKK3 KO cells. Mean and SD are shown in the 
graphs. Experiments have been conducted in octuplicate. ***, P < 0.001 as calculated by 
*** 
24h 
72h *** 
*** *** 
*** p< 0,001 *** p< 0,001 
*** 
*** p< 0,001 
*** 
*** 
*** p< 0,001 *** p< 0,001 
A) 
B) 
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t-Test. B) MEKK3 knocked-out reduces the colony size of PC cell lines. Colony 
Formation Assay of  Panc1, AsPC1 and MDA-Panc28 control or MEKK3 KO cells. 
Mean and SD from 2 independent experiments conducted in triplicate are shown. ***, P < 
0.001 as calculated by t-Test. 
 
 
 
4.2.3 MEKK3 knock-out affects tumor growth and survival in vivo 
in Panc1 and AsPC1 pancreatic tumor orthotopic xenografts. 
 
To demonstrate that MEKK3 is an important mediator for the malignancy 
of PC in vivo, we evaluated whether MEKK3 KO could affect orthotopic 
tumors growth. Six mice for each human PC cell line were orthotopically 
injected and the tumor growth was followed during all their lifespan. Only one 
out of six mice (1/6) injected with MEKK3 KO MDA-Panc28 cells while four 
out of six mice (4/6) injected with MDA-Panc28 control cells developed 
tumors. Hence, we could not use these animals for survival analyses. We 
observed that knocking out MEKK3 in Panc1 and AsPC1 reduced the tumor 
growth in in vivo experiments. In particular, we revealed that mice injected 
with MEKK3 KO Panc1 and AsPC1 presented a strong decrease in tumor 
volume if compared with mice injected with wild-type cells (Fig. 14 A,B). 
According to these data, we observed that mice injected with MEKK3 KO 
Panc1 demonstrated a significantly prolonged median survival duration as 
compared to mice injected with the control cell line, from 65 to 85 days for 
Panc1 (p=0.0306) (Fig 14 C). For MEKK3 KO AsPC1, we observed only a 
trend in prolonged median survival as compared with the control cell line, due 
to non-tumor related death of two mice. All these data demonstrated an 
involvement of MEKK3 in driving tumor malignancy in vivo.  
 
 
 
A) B) 
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Fig. 14 MEKK3 KO affects tumors growth and survival of Panc1 and AsPC1 
pancreatic tumors. A-B) Tumor volume was quantified as the average of fluorescence 
emitted in Panc1 (A) and as the average of all detected photons within the region of the 
tumor per second in AsPC1 (B). Error bars indicate SEM. C) Mice were killed by cervical 
dislocation when evidence of advanced bulky disease was present. Survival was estimated 
from the day of PC cells orthotopic injection until the day of death. Differences among 
survival duration of mice in each group were determined by log-rank test. *, P < 0.05. 
 
 
 
4.2.4 MEKK3 does not affect the NF-κB pathway, while it inhibits 
YAP/TAZ activity in pancreatic cancer cells. 
 
Previous studies have demonstrated that NF-κB is one of the major 
pathways regulated by MEKK3. As Carbone et al. have reported a main role 
for NF-κB in driving the aggressive features of PC 177, we investigated 
whether MEKK3 knock-out could impair the activation of the NF-κB 
pathway. First we analyzed the phosphorylation status of p65, one of the main 
subunits involved in NF-κB hetero-dimer formation, in MEKK3 KO cell lines. 
Unfortunately, we did not observed any alteration in p65 phosphorylation and 
* p <0,05 
* 
C) 
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total protein levels upon knocking out MEKK3 in comparison to parental cell 
lines (Fig. 15A). To further investigate whether MEKK3 could regulate the 
transcriptional activity of NF-κB, we measured the expression of several NF-
κB-target genes by qRT-PCR. As reported in Fig. 15B,  we did not observed 
any even downregulation of NF-κB target genes in all three MEKK3 KO PC 
cell lines, suggesting that MEKK3 does not play a central role in the 
regulation of NF-κB pathway in PC. 
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Fig. 15 MEKK3 KO does not impair  the phosphorylation of p65 and partially 
affects the NFkB target genes expression in PC cell lines . A) Cellular extracts from Panc1, 
AsPC1 and MDA-Panc28 control and MEKK3 KO cell lines were subjected to Western blot 
analysis of phosphorylated and total p65. B) Histograms show  mRNA levels of the indicated 
target genes over β-actin as assessed by qRT-PCR. Mean values and SD are shown. T-test has 
been used to perform statistical analysis. ***, P < 0.001; **,P<0.01; *, P <0,05. 
 
 
 
The YAP/TAZ pathway is emerging as a master regulator of PC malignancy. In order to 
investigate whether MEKK3 could affect this pathway, we first investigated YAP/TAZ 
protein levels in all three PC cell lines upon knocking out MEKK3. By Western 
blot analyses, we did not observe any reduction of YAP/TAZ protein levels in 
MEKK3 KO cell lines in comparison with their controls (Fig. 16A). Likewise, we 
did not measure any reduction of YAP/TAZ mRNA upon MEKK3 KO (Fig. 16B), 
suggesting that MEKK3 in not involved in the regulation of YAP/TAZ stability 
 
 
 
 
Fig. 16 MEKK3 KO does not affect YAP/TAZ expression. A) Cellular extracts from Panc1, 
AsPC1 e MDA-Panc28 control and MEKK3 KO cells were subjected to Western blot analysis 
for the expression of YAP/TAZ. B) Histograms show fold change in RNA expression of 
YAP/TAZ genes by qRT-PCR analysis. Mean values and SD are shown. T-test has been used 
to perform statistical analysis. ***, P < 0.001; **,P<0.01. 
A) 
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To further investigate whether MEKK3 could affect the activity of YAP/TAZ 
transcriptional cofactors, we measured the expression of well-known YAP/TAZ 
target genes. Interestingly, as reported in the table 2, we observed a downregulation 
of AXL, DKK1, CTGF, BDNF and FosL1 expression upon MEKK3 KO in all PC 
lines under investigation (Fig. 17A). Likewise, we revealed a decrease of AXL 
protein levels in MEKK3 KO cell lines (Fig. 17B).  
 
 Panc1 
MEKK3 KO/ctrl 
AsPC1 
MEKK3 KO/ctrl 
MDA-Panc28 
MEKK3 KO/ctrl 
CTGF 0.70 ± 0.21  0.36 ± 0.19 1.25 ± 0.1 
AXL 0.64 ± 0.21 0.34 ± 0.19 0.80 ± 0.065 
DKK1 0.36 ± 0.2 0.62 ± 0.19 0.23 ± 0.05 
FosL1 0.68 ± 0.12 0.42 ± 0.05 0.87 ± 0.09 
BDNF 0.38 ± 0.24 0.46 ± 0.18 0.7 ± 0.1 
 
Table 2 Different expression of YAP/TAZ target genes in Panc1, AsPC1 and MDA-
Panc28 control and MEKK3 KO. 
 
 
Fig. 17 MEKK3 KO reduces the expression of YAP/TAZ target genes. A) Histograms show 
mRNA levels of the indicated target genes over β-actin as assessed by qRT-PCR Mean values and 
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SD are shown. T-test has been used to perform statistical analysis. ***, P < 0.001; **,P<0.01; *, P 
<0,05. B) Western blot analysis for the expression of AXL in the indicated cells.  
 
 
 
These data point out the possibility that MEKK3 might affect the recruitment of 
YAP/TAZ on different target promoters. To verify this hypothesis, we carried out a 
Chromatin Immunoprecipitation (ChIP) assay and we measured a reduction of YAP/TAZ 
binding to the promoters of AXL, DKK1 and CTGF in MEKK3 knocked-out Panc1 cells 
as compared to their controls (Fig. 18). 
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Fig. 18 MEKK3 KO reduces the binding of YAP/TAZ to the promoter regions of AXL, 
DKK1 and CTGF. Chromatin has been immunoprecipitated with the indicated antibodies and 
normalized to starting input chromatin as described in the materials and methods section. 
Histograms show fold increase over control (IgG). Mean values and SD are shown. T-test has been 
used to perform statistical analysis. *,P<0.05. 
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4.2.5 Discussion 
 
MEKK3 is a serine/threonine kinase able to regulate embryonic development 
113
. 
Only recently, it has been demonstrated that MEKK3 is important in orchestrating  
the aggressive behavior of different tumors 
114,115
. To our knowledge, our study is 
the first to evaluate the role of MEKK3 in PC and, in particular, its involvement in 
regulating EMT features. 
In breast cancer, overexpression of MEKK3 is correlated with metastatization of 
cancer cells. In particular, MEKK3 impacts on both EMT through an induction of 
mesenchymal marker vimentin, and migration by increasing ICAM1 protein levels 
118
. In accordance to this study, we observed that MEKK3 drives EMT in PC cell 
lines. In particular, we demonstrated that knock-out of MEKK3 is correlated to 
both an increase of the epithelial marker E-cadherin (Fig.12C) and to a reduction 
in migration of PC cells (Fig. 12D).  
Our data clearly demonstrated that the knock-out of MEKK3 impaired the 
proliferation of PC cells (Fig. 13A). Similar results have been reported in lung 
cancer cells as well. Silencing of MEKK3 impairs the proliferation of lung cancer 
cells by inhibiting the expression of some important cell proliferation inducing 
genes, such as CDK2, CDC25A, CCND1/2 and CCNE1 
114
. Their downregulation 
arrests cells in the G1/S phase and supports the evidence that MEKK3 could 
regulate the cell cycle. In addition, we observed a significant decrease in colony 
size (Fig. 13B) of PC cells knocked out for MEKK3. The reduction in stemness 
ability could be related to a downregulation of the YAP/TAZ pathway and, based 
on data by Tackhoon et al., to a reduction in the expression of IL6 
147
. They have 
demonstrated that YAP cooperates with Serum Response Factor (SRF) in order to 
promote the expression of interleukin-6 (IL6), one of the main secreted factors 
that regulates the stemness-promoting activity of YAP 
147
. IL6 plays a central role 
in stemness and metastasis of solid tumors, but the mechanisms underling IL6 
regulation of these processes remain unclear. Wang et al. have demonstrated that 
IL6 triggers both the stemness and the metastatic potential of hepatocellular 
carcinoma through the induction of osteopontin (OPN) and other stemness-
releated genes 
178
. In addition to these studies, it has been shown that IL6-
knockout mice display resistance to various tumorigenic insults to the liver 
179
, 
skin 
180
 and intestine 
181
, suggesting a role of IL6 in  promoting carcinogenesis in 
vivo 
147
. Interestingly, it has been demonstrated that MEKK3 is one of the main 
drivers in regulating the expression of IL6 in different cellular types 
83,90
. 
Additional studies will be necessary to evaluate whether MEKK3 might regulate 
the expression of IL6 also in PC, thus promoting both the stemness and the 
metastatic behavior of this tumor. 
Altogether, these data demonstrate for the first time that MEKK3 is able to 
regulate the aggressive features of PC cells in in vitro experiments. 
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In order to confirm these results and to validate MEKK3 as a druggable target for 
treatment of patients harboring PC, we evaluated the effect of MEKK3 on the 
growth of pancreatic tumors in in vivo experiments. We observed that knock-out 
of MEKK3 strongly reduced the tumor size of orthotopic tumors established from 
Panc1 (Fig. 14A) and AsPC1 (Fig.14B) cell lines. Moreover we measured a 
significant increase in the median survival of mice injected with Panc1 cells 
knocked out for MEKK3 (Fig. 14C). These data demonstrate that MEKK3 
mediates the aggressive behavior of PC in vivo. Thus, MEKK3 could represent a 
good candidate for the design of drugs to treat PC.  
Two of the most important pathways that orchestrate the aggressiveness of PC are 
NF-κB and YAP/TAZ pathways 148,149,163,177. Our recent study has demonstrated 
that the activation of NF-κB mediated by TAK1 is the partially responsible for the 
chemoresistance of PC 
57
. Different studies have demonstrated that MEKK3 could 
affect directly, or indirectly through TAK1, the activation of NF-κB transcription 
factors 
50,87,88
. In this regard, we evaluated whether MEKK3 could regulate NF-κB 
activation also in PC. Our results demonstrated that the knock-out of MEKK3 did 
not affect NF-κB in PC, suggesting that TAK1 is the main regulator of NF-κB in 
this tumor. We also evaluated whether YAP/TAZ pathway could be affected by 
MEKK3 in PC. Although we did not measure any reduction in YAP/TAZ proteins 
(Fig. 16A) and mRNA levels (Fig. 16B), we observed a significant dowregulation 
of YAP/TAZ target genes upon MEKK3 knock-out (Fig. 17). Thus, we 
hypothesized that MEKK3 could regulate the recruitment of either YAP/TAZ 
themselves or additional cofactors on their target genes. Indeed, we found that 
knock-out of MEKK3 impaired the binding of YAP/TAZ to their target 
promoters, such as AXL, DKK1 and CTGF (Fig. 18). To our knowledge, our data 
demonstrate for the first time that MEKK3 regulates YAP/TAZ activity in cancer 
cells. Recently, Zhang et al. have demonstrated that ERK and another unknown 
kinase regulate YAP activity through specific phosphorylation and/or other post-
translational modifications 
148
. In light of our data, we can envision MEKK3 as 
the unknown kinase regulating YAP activities. However, additional experiments 
are necessary to identify the mechanisms by which MEKK3 affects YAP 
activation. In conclusion, our work identifies MEKK3 as a regulator of the 
aggressiveness of PC, by sustaining the activation of YAP/TAZ and opens the need 
to identify MEKK3 inhibitors in order to impair the invasiveness and metastatic 
behavior of PC. 
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5. Conclusions 
 
In conclusion, our work shows the convergence of two MAP3Ks, TAK1 and 
MEKK3, in regulating the YAP/TAZ transcription cofactors. In particular, TAK1 
promotes the stability of YAP/TAZ by modulating the expression of ITCH and 
TRAF6, while MEKK3 regulates the transcriptional activity of YAP and TAZ in 
PC cells by still unknown mechanisms. The emerging role of YAP/TAZ in 
orchestrating the development and the aggressiveness of PC opens the need for the 
discovery of drugs to inhibit their activities. However, so far, there are no drugs 
targeting specifically the YAP/TAZ pathway and the design of molecules which 
could target transcriptional cofactors is challenging. In light of this, our data open 
the path for targeting the YAP/TAZ pathway through pharmacological inhibition 
of MEKK3 and GSK3/TAK1. Most significantly, this study may candidate the 
suppression of TAK1 and MEKK3 as novel strategies to potentiate the clinical 
activity of chemotherapy for the treatment of PC patients. 
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